<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20409311</article-id><article-id pub-id-type="pmc">2888787</article-id><article-id pub-id-type="publisher-id">1471-2407-10-155</article-id><article-id pub-id-type="doi">10.1186/1471-2407-10-155</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>The lung cancer exercise training study: a randomized trial of aerobic training, resistance training, or both in postsurgical lung cancer patients: rationale and design</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Jones</surname><given-names>Lee W</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jones442@mc.duke.edu</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Eves</surname><given-names>Neil D</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>neves@ukin.ucalgary.ca</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Kraus</surname><given-names>William E</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>william.kraus@duke.edu</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Potti</surname><given-names>Anil</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>anil.potti@duke.edu</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Crawford</surname><given-names>Jeffrey</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jeffrey.crawford@duke.edu</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Blumenthal</surname><given-names>James A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>james.blumenthal@duke.edu</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Peterson</surname><given-names>Bercedis L</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>bercedis.peterson@duke.edu</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Douglas</surname><given-names>Pamela S</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>pamela.douglas@duke.edu</email></contrib></contrib-group><aff id="I1"><label>1</label>Duke University Medical Center, Durham, NC, USA</aff><aff id="I2"><label>2</label>University of Calgary, Calgary, Alberta, Canada</aff><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>21</day><month>4</month><year>2010</year></pub-date><volume>10</volume><fpage>155</fpage><lpage>155</lpage><history><date date-type="received"><day>29</day><month>1</month><year>2010</year></date><date date-type="accepted"><day>21</day><month>4</month><year>2010</year></date></history><permissions><copyright-statement>Copyright ©2010 Jones et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2010</copyright-year><copyright-holder>Jones et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2407/10/155"></self-uri><abstract><sec><title><offsets xml_i="4023" xml_f="4033" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="4044" xml_f="4048" txt_i="22" txt_f="26">The </offsets><underline><offsets xml_i="4059" xml_f="4061" txt_i="26" txt_f="28">Lu</offsets></underline><offsets xml_i="4073" xml_f="4078" txt_i="28" txt_f="33">ng Ca</offsets><underline><offsets xml_i="4089" xml_f="4090" txt_i="33" txt_f="34">n</offsets></underline><offsets xml_i="4102" xml_f="4106" txt_i="34" txt_f="38">cer </offsets><underline><offsets xml_i="4117" xml_f="4118" txt_i="38" txt_f="39">E</offsets></underline><offsets xml_i="4130" xml_f="4134" txt_i="39" txt_f="43">xerc</offsets><underline><offsets xml_i="4145" xml_f="4146" txt_i="43" txt_f="44">i</offsets></underline><offsets xml_i="4158" xml_f="4161" txt_i="44" txt_f="47">se </offsets><underline><offsets xml_i="4172" xml_f="4173" txt_i="47" txt_f="48">T</offsets></underline><offsets xml_i="4185" xml_f="4197" txt_i="48" txt_f="60">raining Stud</offsets><underline><offsets xml_i="4208" xml_f="4209" txt_i="60" txt_f="61">y</offsets></underline><offsets xml_i="4221" xml_f="4356" txt_i="61" txt_f="196"> (LUNGEVITY) is a randomized trial to investigate the efficacy of different types of exercise training on cardiorespiratory fitness (VO</offsets><sub><offsets xml_i="4361" xml_f="4366" txt_i="196" txt_f="201">2peak</offsets></sub><offsets xml_i="4372" xml_f="4441" txt_i="201" txt_f="270">), patient-reported outcomes, and the organ components that govern VO</offsets><sub><offsets xml_i="4446" xml_f="4452" txt_i="270" txt_f="276">2peak </offsets></sub><offsets xml_i="4458" xml_f="4520" txt_i="276" txt_f="338">in post-operative non-small cell lung cancer (NSCLC) patients.</offsets></p></sec><sec><title><offsets xml_i="4542" xml_f="4556" txt_i="340" txt_f="354">Methods/Design</offsets></title><p><offsets xml_i="4567" xml_f="5263" txt_i="355" txt_f="1051">Using a single-center, randomized design, 160 subjects (40 patients/study arm) with histologically confirmed stage I-IIIA NSCLC following curative-intent complete surgical resection at Duke University Medical Center (DUMC) will be potentially eligible for this trial. Following baseline assessments, eligible participants will be randomly assigned to one of four conditions: (1) aerobic training alone, (2) resistance training alone, (3) the combination of aerobic and resistance training, or (4) attention-control (progressive stretching). The ultimate goal for all exercise training groups will be 3 supervised exercise sessions per week an intensity above 70% of the individually determined VO</offsets><sub><offsets xml_i="5268" xml_f="5274" txt_i="1051" txt_f="1057">2peak </offsets></sub><offsets xml_i="5280" xml_f="5660" txt_i="1057" txt_f="1437">for aerobic training and an intensity between 60 and 80% of one-repetition maximum for resistance training, for 30-45 minutes/session. Progressive stretching will be matched to the exercise groups in terms of program length (i.e., 16 weeks), social interaction (participants will receive one-on-one instruction), and duration (30-45 mins/session). The primary study endpoint is VO</offsets><sub><offsets xml_i="5665" xml_f="5670" txt_i="1437" txt_f="1442">2peak</offsets></sub><offsets xml_i="5676" xml_f="6253" txt_i="1442" txt_f="2019">. Secondary endpoints include: patient-reported outcomes (PROs) (e.g., quality of life, fatigue, depression, etc.) and organ components of the oxygen cascade (i.e., pulmonary function, cardiac function, skeletal muscle function). All endpoints will be assessed at baseline and postintervention (16 weeks). Substudies will include genetic studies regarding individual responses to an exercise stimulus, theoretical determinants of exercise adherence, examination of the psychological mediators of the exercise - PRO relationship, and exercise-induced changes in gene expression.</offsets></p></sec><sec><title><offsets xml_i="6275" xml_f="6285" txt_i="2021" txt_f="2031">Discussion</offsets></title><p><offsets xml_i="6296" xml_f="6298" txt_i="2032" txt_f="2034">VO</offsets><sub><offsets xml_i="6303" xml_f="6309" txt_i="2034" txt_f="2040">2peak </offsets></sub><offsets xml_i="6315" xml_f="6721" txt_i="2040" txt_f="2446">is becoming increasingly recognized as an outcome of major importance in NSCLC. LUNGEVITY will identify the optimal form of exercise training for NSCLC survivors as well as provide insight into the physiological mechanisms underlying this effect. Overall, this study will contribute to the establishment of clinical exercise therapy rehabilitation guidelines for patients across the entire NSCLC continuum.</offsets></p></sec><sec><title><offsets xml_i="6743" xml_f="6761" txt_i="2448" txt_f="2466">Trial Registration</offsets></title><p><offsets xml_i="6772" xml_f="6783" txt_i="2467" txt_f="2478">NCT00018255</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="6845" xml_f="6855" txt_i="2487" txt_f="2497">Background</offsets></title><p><offsets xml_i="6866" xml_f="7435" txt_i="2498" txt_f="3067">Improvements in surgical techniques together with more effective adjuvant chemotherapeutic regimens has led to significant survival benefit for individuals with non-small cell lung cancer (NSCLC). Approximately 26,000 individuals per year in the United States will survive more than 5 years after initial diagnosis of operable disease. With improving prognosis, acute and long-term disease - and treatment-related morbidity (symptom control) and mortality are now recognized as issues of major clinical importance in the multidisciplinary management of operable NSCLC [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="7466" xml_f="7467" txt_i="3067" txt_f="3068">1</offsets></xref><offsets xml_i="7474" xml_f="7475" txt_i="3068" txt_f="3069">-</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="7506" xml_f="7507" txt_i="3069" txt_f="3070">6</offsets></xref><offsets xml_i="7514" xml_f="7834" txt_i="3070" txt_f="3390">]. A parameter of central importance that may mediate acute and late-occurring disease and treatment-related toxicity in lung cancer survivorship is cardiorespiratory fitness. Cardiorespiratory fitness, as measured by an objective exercise tolerance test, reflects the integrative capacity of components in the oxygen (O</offsets><sub><offsets xml_i="7839" xml_f="7840" txt_i="3390" txt_f="3391">2</offsets></sub><offsets xml_i="7846" xml_f="7876" txt_i="3391" txt_f="3421">) cascade to supply adequate O</offsets><sub><offsets xml_i="7881" xml_f="7883" txt_i="3421" txt_f="3423">2 </offsets></sub><offsets xml_i="7889" xml_f="7962" txt_i="3423" txt_f="3496">for adenosine triphosphate (ATP) resynthesis. Peak oxygen consumption (VO</offsets><sub><offsets xml_i="7967" xml_f="7972" txt_i="3496" txt_f="3501">2peak</offsets></sub><offsets xml_i="7978" xml_f="8226" txt_i="3501" txt_f="3749">) provides the gold standard (direct) assessment of cardiorespiratory fitness. Direct or estimated measurement of cardiorespiratory fitness is a well-established independent predictor of mortality in a broad range of non-cancer, adult populations [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="8257" xml_f="8258" txt_i="3749" txt_f="3750">7</offsets></xref><offsets xml_i="8265" xml_f="8266" txt_i="3750" txt_f="3751">,</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="8297" xml_f="8298" txt_i="3751" txt_f="3752">8</offsets></xref><offsets xml_i="8305" xml_f="8307" txt_i="3752" txt_f="3754">].</offsets></p><p><offsets xml_i="8314" xml_f="8400" txt_i="3755" txt_f="3841">Not surprisingly, operable NSCLC patients have significant and marked reductions in VO</offsets><sub><offsets xml_i="8405" xml_f="8410" txt_i="3841" txt_f="3846">2peak</offsets></sub><offsets xml_i="8416" xml_f="8607" txt_i="3846" txt_f="4037">. Postsurgical NSCLC patients are subject to the effects of normal ageing, age-related and/or disease-related comorbid conditions, and deconditioning that adversely impact components of the O</offsets><sub><offsets xml_i="8612" xml_f="8614" txt_i="4037" txt_f="4039">2 </offsets></sub><offsets xml_i="8620" xml_f="8871" txt_i="4039" txt_f="4290">cascade. However, these 'normal' consequences are profoundly accelerated by disease pathophysiology and the use of conventional adjuvant therapy to create a 'perfect deconditioning storm', reducing either the body's ability to deliver and/or utilize O</offsets><sub><offsets xml_i="8876" xml_f="8878" txt_i="4290" txt_f="4292">2 </offsets></sub><offsets xml_i="8884" xml_f="8916" txt_i="4292" txt_f="4324">and substrate leading to poor VO</offsets><sub><offsets xml_i="8921" xml_f="8926" txt_i="4324" txt_f="4329">2peak</offsets></sub><offsets xml_i="8932" xml_f="8933" txt_i="4329" txt_f="4330">[</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="8964" xml_f="8965" txt_i="4330" txt_f="4331">9</offsets></xref><offsets xml_i="8972" xml_f="9050" txt_i="4331" txt_f="4409">]. Such effects have important implications across the entire NSCLC continuum[</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="9082" xml_f="9084" txt_i="4409" txt_f="4411">10</offsets></xref><offsets xml_i="9091" xml_f="9093" txt_i="4411" txt_f="4413">].</offsets></p><p><offsets xml_i="9100" xml_f="9122" txt_i="4414" txt_f="4436">First, preoperative VO</offsets><sub><offsets xml_i="9127" xml_f="9133" txt_i="4436" txt_f="4442">2peak </offsets></sub><offsets xml_i="9139" xml_f="9250" txt_i="4442" txt_f="4553">is a well-established risk stratification tool to determine perioperaitve and postoperative complication risk [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="9282" xml_f="9284" txt_i="4553" txt_f="4555">11</offsets></xref><offsets xml_i="9291" xml_f="9292" txt_i="4555" txt_f="4556">-</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="9324" xml_f="9326" txt_i="4556" txt_f="4558">14</offsets></xref><offsets xml_i="9333" xml_f="9367" txt_i="4558" txt_f="4592">]. Second, following resection, VO</offsets><sub><offsets xml_i="9372" xml_f="9378" txt_i="4592" txt_f="4598">2peak </offsets></sub><offsets xml_i="9384" xml_f="9453" txt_i="4598" txt_f="4667">as well as self-reported exercise behavior (a major determinant of VO</offsets><sub><offsets xml_i="9458" xml_f="9463" txt_i="4667" txt_f="4672">2peak</offsets></sub><offsets xml_i="9469" xml_f="9582" txt_i="4672" txt_f="4785">), are strong predictors of patient-reported outcomes (PROs) such as overall QOL, fatigue, and other QOL domains[</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="9614" xml_f="9616" txt_i="4785" txt_f="4787">15</offsets></xref><offsets xml_i="9623" xml_f="9672" txt_i="4787" txt_f="4836">]. Finally, our group found that pre-operative VO</offsets><sub><offsets xml_i="9677" xml_f="9683" txt_i="4836" txt_f="4842">2peak </offsets></sub><offsets xml_i="9689" xml_f="9834" txt_i="4842" txt_f="4987">is a strong independent predictor of overall survival in NSCLC surgical candidates even when controlling for performance status, gender, and age[</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="9866" xml_f="9868" txt_i="4987" txt_f="4989">16</offsets></xref><offsets xml_i="9875" xml_f="9933" txt_i="4989" txt_f="5047">]. In totality, these data provide strong evidence that VO</offsets><sub><offsets xml_i="9938" xml_f="9944" txt_i="5047" txt_f="5053">2peak </offsets></sub><offsets xml_i="9950" xml_f="10094" txt_i="5053" txt_f="5197">is an attractive modifiable therapeutic target to improve surgical risk and/or recovery, symptom control and possibly, disease outcome in NSCLC.</offsets></p><p><offsets xml_i="10101" xml_f="10258" txt_i="5198" txt_f="5355">Chronic, repeated aerobic training (i.e., continuous activity involving large muscle groups) is widely established as the most effective method to improve VO</offsets><sub><offsets xml_i="10263" xml_f="10269" txt_i="5355" txt_f="5361">2peak </offsets></sub><offsets xml_i="10275" xml_f="10371" txt_i="5361" txt_f="5457">in healthy humans although a paucity of studies have investigated the role of exercise in NSCLC[</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="10403" xml_f="10405" txt_i="5457" txt_f="5459">10</offsets></xref><offsets xml_i="10412" xml_f="10826" txt_i="5459" txt_f="5873">]. Given the preliminary nature of this field, we recently completed two uncontrolled pilot studies investigating the feasibility and preliminary efficacy of supervised aerobic training in the pre-operative and post-operative setting in NSCLC. Results of these pilot studies provided 'proof of principle' that aerobic training is a safe and feasible intervention for NSCLC patients, however, the improvements in VO</offsets><sub><offsets xml_i="10831" xml_f="10837" txt_i="5873" txt_f="5879">2peak </offsets></sub><offsets xml_i="10843" xml_f="10982" txt_i="5879" txt_f="6015">were modest (&lt;15%), particularly in the post-operative setting (~10%) despite good exercise adherence rates (≥70% of planned sessions) [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="11014" xml_f="11016" txt_i="6015" txt_f="6017">17</offsets></xref><offsets xml_i="11023" xml_f="11024" txt_i="6017" txt_f="6018">,</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="11056" xml_f="11058" txt_i="6018" txt_f="6020">18</offsets></xref><offsets xml_i="11065" xml_f="11067" txt_i="6020" txt_f="6022">].</offsets></p><p><offsets xml_i="11074" xml_f="11129" txt_i="6023" txt_f="6078">The reasons for the relatively modest improvement in VO</offsets><sub><offsets xml_i="11134" xml_f="11140" txt_i="6078" txt_f="6084">2peak </offsets></sub><offsets xml_i="11146" xml_f="11227" txt_i="6084" txt_f="6165">in NSCLC relative to other clinical populations (i.e., ~15%-20% improvement in VO</offsets><sub><offsets xml_i="11232" xml_f="11238" txt_i="6165" txt_f="6171">2peak </offsets></sub><offsets xml_i="11244" xml_f="11534" txt_i="6171" txt_f="6461">following traditional aerobic training recommendations) remain to be elucidated. An obvious potential explanation is a ventilatory limitation or inadequate gas exchange following removal of a substantial portion of lung parenchyma. However, several elegant studies have demonstrated that VO</offsets><sub><offsets xml_i="11539" xml_f="11545" txt_i="6461" txt_f="6467">2peak </offsets></sub><offsets xml_i="11551" xml_f="11604" txt_i="6467" txt_f="6520">is not limited by ventilation or diffusion capacity [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="11636" xml_f="11638" txt_i="6520" txt_f="6522">19</offsets></xref><offsets xml_i="11645" xml_f="11646" txt_i="6522" txt_f="6523">-</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="11678" xml_f="11680" txt_i="6523" txt_f="6525">22</offsets></xref><offsets xml_i="11687" xml_f="11790" txt_i="6525" txt_f="6628">] suggesting that exercise-induced adaptations (or lack thereof) in the other organ components of the O</offsets><sub><offsets xml_i="11795" xml_f="11797" txt_i="6628" txt_f="6630">2 </offsets></sub><offsets xml_i="11803" xml_f="11830" txt_i="6630" txt_f="6657">cascade are responsible. VO</offsets><sub><offsets xml_i="11835" xml_f="11841" txt_i="6657" txt_f="6663">2peak </offsets></sub><offsets xml_i="11847" xml_f="11920" txt_i="6663" txt_f="6736">in NSCLC patients is likely principally governed by poor cardiovascular O</offsets><sub><offsets xml_i="11925" xml_f="11927" txt_i="6736" txt_f="6738">2 </offsets></sub><offsets xml_i="11933" xml_f="11965" txt_i="6738" txt_f="6770">delivery and oxidative capacity </offsets><italic><offsets xml_i="11973" xml_f="11984" txt_i="6770" txt_f="6781">as well as </offsets></italic><offsets xml_i="11993" xml_f="12430" txt_i="6781" txt_f="7218">unfavorable fiber type distribution and muscle atrophy/weakness similar to the limitations to exercise described in patients with chronic obstructive pulmonary disease (COPD). Major contributors to skeletal muscle dysfunction in NSCLC likely include direct skeletal myopathy (from the use of oral corticosteroids), deconditioning (from physical inactivity), and high levels of systemic inflammation (from underlying disease and therapy)[</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="12462" xml_f="12464" txt_i="7218" txt_f="7220">23</offsets></xref><offsets xml_i="12471" xml_f="12473" txt_i="7220" txt_f="7222">].</offsets></p><p><offsets xml_i="12480" xml_f="12552" txt_i="7223" txt_f="7295">Importantly, aerobic training will cause favorable adaptations in most O</offsets><sub><offsets xml_i="12557" xml_f="12559" txt_i="7295" txt_f="7297">2 </offsets></sub><offsets xml_i="12565" xml_f="13145" txt_i="7297" txt_f="7877">transport components but will not reverse skeletal muscle atrophy/weakness and will only partially reverse a more glycolytic fiber type distribution. Thus, aerobic training alone may be insufficient to ameliorate skeletal muscle dysfunction likely manifest in NSCLC. Standard resistance training (i.e., activity involving the acute exertion of force) performed according to standard guidelines (i.e., 2-5 times/week, 50%-80% of 1 repetition maximum for 12-24 weeks) is unequivocally acknowledged as the most effective method to improve skeletal muscle function in human subjects [</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="13177" xml_f="13179" txt_i="7877" txt_f="7879">24</offsets></xref><offsets xml_i="13186" xml_f="13187" txt_i="7879" txt_f="7880">-</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="13219" xml_f="13221" txt_i="7880" txt_f="7882">28</offsets></xref><offsets xml_i="13228" xml_f="13320" txt_i="7882" txt_f="7974">]. Moreover, in severely deconditioned adults, resistance training causes improvements in VO</offsets><sub><offsets xml_i="13325" xml_f="13331" txt_i="7974" txt_f="7980">2peak </offsets></sub><offsets xml_i="13337" xml_f="13338" txt_i="7980" txt_f="7981">[</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="13370" xml_f="13372" txt_i="7981" txt_f="7983">29</offsets></xref><offsets xml_i="13379" xml_f="13380" txt_i="7983" txt_f="7984">-</offsets><xref ref-type="bibr" rid="B34"><offsets xml_i="13412" xml_f="13414" txt_i="7984" txt_f="7986">34</offsets></xref><offsets xml_i="13421" xml_f="13577" txt_i="7986" txt_f="8142">] although the mechanisms underlying this effect are not clearly understood. In theory, while aerobic and resistance training might independently improve VO</offsets><sub><offsets xml_i="13582" xml_f="13588" txt_i="8142" txt_f="8148">2peak </offsets></sub><offsets xml_i="13594" xml_f="13789" txt_i="8148" txt_f="8343">in NSCLC, such improvements are likely to be modest (~10%). Instead, the combination of aerobic and resistance training may be the most effective form of exercise training to optimally augment VO</offsets><sub><offsets xml_i="13794" xml_f="13799" txt_i="8343" txt_f="8348">2peak</offsets></sub><offsets xml_i="13805" xml_f="13917" txt_i="8348" txt_f="8460">. The complementary physiologic adaptations from the combination approach will result in higher cardiovascular O</offsets><sub><offsets xml_i="13922" xml_f="13924" txt_i="8460" txt_f="8462">2 </offsets></sub><offsets xml_i="13930" xml_f="14319" txt_i="8462" txt_f="8851">delivery, skeletal muscle oxidative phosphoryation, muscle strength and optimal fiber type composition leading to higher muscle endurance, reduced fatiguability, a higher threshold to the metabolic waste products of exercise, and reduced ventilatory requirements during exercise. This approach is hypothesized to maximize physiologic adaptations in the principal factors underlying poor VO</offsets><sub><offsets xml_i="14324" xml_f="14330" txt_i="8851" txt_f="8857">2peak </offsets></sub><offsets xml_i="14336" xml_f="14428" txt_i="8857" txt_f="8949">in postsurgical NSCLC patients more effectively than either exercise modality alone (Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="14458" xml_f="14459" txt_i="8949" txt_f="8950">1</offsets></xref><offsets xml_i="14466" xml_f="14468" txt_i="8950" txt_f="8952">).</offsets></p><fig id="F1" position="float"><label><offsets xml_i="14509" xml_f="14517" txt_i="8953" txt_f="8961">Figure 1</offsets></label><caption><p><bold><offsets xml_i="14543" xml_f="14741" txt_i="8961" txt_f="9159">Hypothesized effects of aerobic training alone, resistance training alone, and aerobic plus resistance training on the components of the oxygen cascade and resultant impact on exercise tolerance (VO</offsets><sub><offsets xml_i="14746" xml_f="14751" txt_i="9159" txt_f="9164">2peak</offsets></sub><offsets xml_i="14757" xml_f="14758" txt_i="9164" txt_f="9165">)</offsets></bold><offsets xml_i="14765" xml_f="14766" txt_i="9165" txt_f="9166">.</offsets></p></caption><graphic xlink:href="1471-2407-10-155-1"></graphic></fig><p><offsets xml_i="14840" xml_f="14881" txt_i="9167" txt_f="9208">Against this background, we designed the </offsets><underline><offsets xml_i="14892" xml_f="14894" txt_i="9208" txt_f="9210">Lu</offsets></underline><offsets xml_i="14906" xml_f="14911" txt_i="9210" txt_f="9215">ng Ca</offsets><underline><offsets xml_i="14922" xml_f="14923" txt_i="9215" txt_f="9216">n</offsets></underline><offsets xml_i="14935" xml_f="14944" txt_i="9216" txt_f="9225">cer Exerc</offsets><underline><offsets xml_i="14955" xml_f="14956" txt_i="9225" txt_f="9226">i</offsets></underline><offsets xml_i="14968" xml_f="14971" txt_i="9226" txt_f="9229">se </offsets><underline><offsets xml_i="14982" xml_f="14983" txt_i="9229" txt_f="9230">T</offsets></underline><offsets xml_i="14995" xml_f="15007" txt_i="9230" txt_f="9242">raining Stud</offsets><underline><offsets xml_i="15018" xml_f="15019" txt_i="9242" txt_f="9243">y</offsets></underline><offsets xml_i="15031" xml_f="15287" txt_i="9243" txt_f="9499"> (LUNGEVITY), a randomized trial to investigate the efficacy of different types of exercise training in post-operative NSCLC patients. The fundamental rationale for this single-center trial is to identify the optimal type of exercise training to improve VO</offsets><sub><offsets xml_i="15292" xml_f="15298" txt_i="9499" txt_f="9505">2peak </offsets></sub><offsets xml_i="15304" xml_f="15551" txt_i="9505" txt_f="9752">in postoperative NSCLC patients and understand the physiologic mechanisms underlying this effect. The specific aims are: (1) to compare the effects of aerobic training alone, resistance training alone, or both, relative to attention-control, on VO</offsets><sub><offsets xml_i="15556" xml_f="15561" txt_i="9752" txt_f="9757">2peak</offsets></sub><offsets xml_i="15567" xml_f="15627" txt_i="9757" txt_f="9817">, (2) determine the effects on the mechanisms that govern VO</offsets><sub><offsets xml_i="15632" xml_f="15638" txt_i="9817" txt_f="9823">2peak </offsets></sub><offsets xml_i="15644" xml_f="15738" txt_i="9823" txt_f="9917">(measurements of the heart-lung-skeletal muscle axis), and (3) to compare the effects on PROs.</offsets></p></sec><sec><title><offsets xml_i="15760" xml_f="15774" txt_i="9919" txt_f="9933">Methods/Design</offsets></title><sec><title><offsets xml_i="15794" xml_f="15818" txt_i="9934" txt_f="9958">Participants and Setting</offsets></title><p><offsets xml_i="15829" xml_f="16290" txt_i="9959" txt_f="10420">In LUNGEVITY, we will recruit and randomize 160 subjects (40 patients/study arm) with histologically confirmed stage I-IIIA NSCLC following curative-intent complete surgical resection at Duke University Medical Center (DUMC). The DUMC institutional review board approved the study and written informed consent will be obtained from all participants prior to initiation of any study procedures. Additional inclusion and exclusion criteria are described in Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="16322" xml_f="16323" txt_i="10420" txt_f="10421">1</offsets></xref><offsets xml_i="16330" xml_f="16331" txt_i="10421" txt_f="10422">.</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="16379" xml_f="16386" txt_i="10423" txt_f="10430">Table 1</offsets></label><caption><p><offsets xml_i="16406" xml_f="16434" txt_i="10430" txt_f="10458">Subject Eligibility Criteria</offsets></p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left"><underline><offsets xml_i="16524" xml_f="16542" txt_i="10459" txt_f="10477">Inclusion Criteria</offsets></underline></td><td></td></tr><tr><td align="left"><offsets xml_i="16594" xml_f="16617" txt_i="10479" txt_f="10502"> At least 21 years old.</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="16657" xml_f="16720" txt_i="10504" txt_f="10567"> An interval of at least 6 months following surgical resection.</offsets></td><td align="left"><offsets xml_i="16742" xml_f="16744" txt_i="10568" txt_f="10570">VO</offsets><sub><offsets xml_i="16749" xml_f="16755" txt_i="10570" txt_f="10576">2peak </offsets></sub><offsets xml_i="16761" xml_f="16980" txt_i="10576" txt_f="10795">has been shown to (spontaneously) recover, to a limited degree, immediately following (~3 months) and stabilize at ~6 months post pulmonary resection. Thus, to accurately determine the effects of exercise training on VO</offsets><sub><offsets xml_i="16985" xml_f="16991" txt_i="10795" txt_f="10801">2peak </offsets></sub><offsets xml_i="16997" xml_f="17136" txt_i="10801" txt_f="10940">in this setting, we felt it was critically important to initiate study procedures (i.e., recruit and randomize patients) once changes in VO</offsets><sub><offsets xml_i="17141" xml_f="17147" txt_i="10940" txt_f="10946">2peak </offsets></sub><offsets xml_i="17153" xml_f="17247" txt_i="10946" txt_f="11040">have stabilized to minimize the effects of natural postsurgical recovery on improvements in VO</offsets><sub><offsets xml_i="17252" xml_f="17257" txt_i="11040" txt_f="11045">2peak</offsets></sub><offsets xml_i="17263" xml_f="17264" txt_i="11045" txt_f="11046">,</offsets></td></tr><tr><td align="left"><offsets xml_i="17295" xml_f="17350" txt_i="11047" txt_f="11102"> An interval of no longer than 36 months post-resection</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="17390" xml_f="17450" txt_i="11104" txt_f="11164"> Karnofsky performance status of at least 70% at study entry</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="17490" xml_f="17529" txt_i="11166" txt_f="11205"> Estimated life expectancy of ≥6 months</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="17569" xml_f="17608" txt_i="11207" txt_f="11246"> Ability to read and understand English</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="17648" xml_f="17686" txt_i="11248" txt_f="11286"> Primary attending oncologist approval</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="17726" xml_f="17736" txt_i="11288" txt_f="11298"> Sedentary</offsets></td><td align="left"><offsets xml_i="17758" xml_f="17929" txt_i="11299" txt_f="11470">Patients not performing regular exercise. Regular exercise is defined as ≥5 days a week, ≥30 minutes each session, at a moderate or vigorous intensity for the past month).</offsets></td></tr><tr><td align="left"><offsets xml_i="17960" xml_f="17989" txt_i="11471" txt_f="11500"> Willingness to be randomized</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="18029" xml_f="18101" txt_i="11502" txt_f="11574"> Signed informed consent prior to initiation of study-related procedures</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="18141" xml_f="18276" txt_i="11576" txt_f="11711"> Reside within driving distance of DUMC, as necessitated by the clinic-based assessments and supervised exercise training interventions</offsets></td><td></td></tr><tr><td></td><td></td></tr><tr><td align="left"><underline><offsets xml_i="18354" xml_f="18372" txt_i="11715" txt_f="11733">Exclusion Criteria</offsets></underline></td><td></td></tr><tr><td align="left"><offsets xml_i="18424" xml_f="18585" txt_i="11735" txt_f="11896"> Presence of a concurrent, actively treated other malignancy or history of other malignancy treated within the past 3 years (other than non-melanoma skin cancer)</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="18625" xml_f="18656" txt_i="11898" txt_f="11929"> Presence of metastatic disease</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="18696" xml_f="18753" txt_i="11931" txt_f="11988"> Scheduled to receive any form of adjuvant cancer therapy</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="18793" xml_f="18939" txt_i="11990" txt_f="12136"> Contraindications to maximal exercise testing as recommended by the American Thoracic Society and exercise testing guidelines for cancer patients</offsets></td><td></td></tr></tbody></table></table-wrap></sec><sec><title><offsets xml_i="19005" xml_f="19015" txt_i="12139" txt_f="12149">Procedures</offsets></title><p><offsets xml_i="19026" xml_f="19176" txt_i="12150" txt_f="12300">The study will be conducted in accordance with the CONSORT (Consolidated Standards of Reporting Trials) statement for non-pharmacologic interventions[</offsets><xref ref-type="bibr" rid="B35"><offsets xml_i="19208" xml_f="19210" txt_i="12300" txt_f="12302">35</offsets></xref><offsets xml_i="19217" xml_f="19258" txt_i="12302" txt_f="12343">]. The study flow is presented in Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="19288" xml_f="19289" txt_i="12343" txt_f="12344">2</offsets></xref><offsets xml_i="19296" xml_f="20634" txt_i="12344" txt_f="13682">. Using a 4-arm, randomized design, potential subjects will be identified and screened for eligibility by the study research coordinators via medical record review of NSCLC patients scheduled to attend a 'follow-up' consultation at DUMC as per standard of care. Following the consultation and primary attending oncologist approval, potential eligible subjects will be provided with a thorough review of the study by the study coordinators and asked if they are willing to participate. Interested participants will be provided with the study consent and baseline study questionnaire. Two to five days following the consultation, interested participants will be contacted by telephone by the study coordinators to answer any questions and to schedule the baseline assessment visit. In addition, to broaden recruitment efforts, subjects previously diagnosed with stage I-IIIA NSCLC within 36 months of diagnosis will be identified through the DUMC tumor registry. Permission to contact potential subjects will be obtained from their attending oncologist and letters of study invitation describing the study co-signed by the principal investigator and attending oncologist will be mailed to all potential subjects. Interested participants will be able to call a toll-free telephone number to obtain more information about study participation.</offsets></p><fig id="F2" position="float"><label><offsets xml_i="20675" xml_f="20683" txt_i="13683" txt_f="13691">Figure 2</offsets></label><caption><p><bold><offsets xml_i="20709" xml_f="20719" txt_i="13691" txt_f="13701">Study Flow</offsets></bold><offsets xml_i="20726" xml_f="20727" txt_i="13701" txt_f="13702">.</offsets></p></caption><graphic xlink:href="1471-2407-10-155-2"></graphic></fig><p><offsets xml_i="20801" xml_f="21601" txt_i="13703" txt_f="14503">At the baseline study visit, all participants will complete the following assessments in order of presentation: (1) fasting blood draw, (2) pulmonary function test (3) cardiopulmonary exercise test, and (4) echocardiogram at rest and exercise. On the following day, patients will perform the following assessments: (1) one repetition maximum lower extremity strength test, and (2) tissue biopsy of the vastus lateralis. Participants will be asked to adhere to a water-only fast for 8 hours prior to testing on both days. All baseline assessments will be repeated at the end of the intervention (i.e., 16 weeks). To maximize internal validity, study endpoint assessments will be conducted by the same personnel, with the same equipment, in the same order (timing) at baseline and follow-up timepoints.</offsets></p></sec><sec><title><offsets xml_i="21623" xml_f="21655" txt_i="14505" txt_f="14537">Group Allocation (Randomization)</offsets></title><p><offsets xml_i="21666" xml_f="22683" txt_i="14538" txt_f="15555">Following the successful completion of baseline assessments, participants will be randomly allocated, on an individual basis, to one of the three exercise interventions (i.e., aerobic training, resistance training, the combination of aerobic and resistance training) or an attention-control group. Randomly allocated participants will remain in the same group for the entire duration of the intervention (i.e., no cross-over). To ensure randomized groups are similar at baseline, patient randomization will be stratified based on gender (men vs. female) and smoking status (current vs. non-smoking). For each gender-smoking status participant subgroup, a computer-generated list of random treatment assignments will be created by Dr. Peterson (trial biostatistician) in sequentially numbered sealed envelopes. The random allocation sequences will be concealed from all study personnel (except Dr. Peterson). A permuted block design with allocation weight of 1:1:1:1 will be used to generate the treatment assignments.</offsets></p></sec><sec><title><offsets xml_i="22705" xml_f="22721" txt_i="15557" txt_f="15573">Blinding/Masking</offsets></title><p><offsets xml_i="22732" xml_f="23472" txt_i="15574" txt_f="16314">Blinding study participants to treatment allocation in clinical trials of exercise training is not possible since participants are aware whether they are exercising or not. Also, it is not possible to blind study personnel monitoring exercise training sessions to the participant group assignment since study personnel are aware whether a participant is performing aerobic or resistance training. Nevertheless, all study personnel conducting the study assessments at baseline and postintervention will be blinded to treatment assignment for the duration of the study. Only the trial statistician and the data monitoring committee will have access to unblinded data, but none will have any contact with study participants or study personnel.</offsets></p></sec><sec><title><offsets xml_i="23494" xml_f="23546" txt_i="16316" txt_f="16368">Exercise Training Protocols (General Considerations)</offsets></title><p><offsets xml_i="23557" xml_f="23712" txt_i="16369" txt_f="16524">The ultimate goal for all exercise training groups will be 3 supervised exercise sessions per week an intensity above 70% of the individually determined VO</offsets><sub><offsets xml_i="23717" xml_f="23723" txt_i="16524" txt_f="16530">2peak </offsets></sub><offsets xml_i="23729" xml_f="23979" txt_i="16530" txt_f="16780">for aerobic training and an intensity between 60 and 80% of one-repetition maximum for resistance training, for 30-90 minutes/session. All the exercise interventions are designed such that participants begin exercising at a low intensity (~50%-60% VO</offsets><sub><offsets xml_i="23984" xml_f="23989" txt_i="16780" txt_f="16785">2peak</offsets></sub><offsets xml_i="23995" xml_f="24079" txt_i="16785" txt_f="16869">) that is subsequently increased to more moderate to vigorous intensity (~70%-80% VO</offsets><sub><offsets xml_i="24084" xml_f="24089" txt_i="16869" txt_f="16874">2peak</offsets></sub><offsets xml_i="24095" xml_f="24338" txt_i="16874" txt_f="17117">) when appropriate. All interventions will be individually tailored to each patient following the principles of aerobic or resistance training prescription guidelines for adults as recommended by the American College of Sports Medicine (ACSM)[</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="24370" xml_f="24372" txt_i="17117" txt_f="17119">24</offsets></xref><offsets xml_i="24379" xml_f="24655" txt_i="17119" txt_f="17395">]. All exercise sessions will also be performed in a supervised setting with one-on-one supervision by an ACSM-certified exercise physiologist. Supervised exercise training sessions are critical to ensure a robust test of exercise training efficacy and safety in this setting.</offsets></p><p><offsets xml_i="24662" xml_f="24855" txt_i="17396" txt_f="17589">All exercise sessions will include a 5-min warm-up and 5-min cool down on either a treadmill or cycle ergometer at the beginning and end of each training session, respectively. Heart rate and O</offsets><sub><offsets xml_i="24860" xml_f="24862" txt_i="17589" txt_f="17591">2 </offsets></sub><offsets xml_i="24868" xml_f="25218" txt_i="17591" txt_f="17941">saturation will be monitored continuously throughout exercise while blood pressure will be assessed prior, during, and immediately following each exercise session. To monitor any exercise performed outside of the supervised sessions, participants will be provided with a heart rate monitor as well as a study exercise log-book to record all sessions.</offsets></p><sec><title><offsets xml_i="25234" xml_f="25269" txt_i="17942" txt_f="17977">Study Arm 1: Aerobic Training Alone</offsets></title><p><offsets xml_i="25280" xml_f="25371" txt_i="17978" txt_f="18069">Aerobic training will be prescribed according to ASCM guidelines and aimed at increasing VO</offsets><sub><offsets xml_i="25376" xml_f="25381" txt_i="18069" txt_f="18074">2peak</offsets></sub><offsets xml_i="25387" xml_f="25500" txt_i="18074" txt_f="18187">. The ultimate goal for aerobic training alone is 3 cycle ergometry sessions/week at an intensity above 70% of VO</offsets><sub><offsets xml_i="25505" xml_f="25511" txt_i="18187" txt_f="18193">2peak </offsets></sub><offsets xml_i="25517" xml_f="25983" txt_i="18193" txt_f="18659">for 30-60 minutes/session. Cycle ergometry was chosen as the mode of aerobic training because exercise prescriptions can be more accurately prescribed and monitored on cycle ergometers than treadmill walking. Also, treadmill walking requires considerable balance; lung cancer patients are typically older, have balance issues, and typically have limited experience with treadmill exercise. Specific details of the aerobic training prescription are provided in Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="26015" xml_f="26016" txt_i="18659" txt_f="18660">2</offsets></xref><offsets xml_i="26023" xml_f="26024" txt_i="18660" txt_f="18661">.</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="26072" xml_f="26079" txt_i="18662" txt_f="18669">Table 2</offsets></label><caption><p><offsets xml_i="26099" xml_f="26129" txt_i="18669" txt_f="18699">Aerobic Training Alone Program</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th></th><th align="center" colspan="3"><offsets xml_i="26240" xml_f="26267" txt_i="18700" txt_f="18727">Supervised Aerobic Training</offsets></th></tr><tr><th></th><th colspan="4"><hr></hr></th></tr><tr><th align="left"><offsets xml_i="26346" xml_f="26360" txt_i="18727" txt_f="18741">Training Phase</offsets></th><th align="center"><offsets xml_i="26384" xml_f="26388" txt_i="18741" txt_f="18745">Week</offsets></th><th align="center"><offsets xml_i="26412" xml_f="26427" txt_i="18745" txt_f="18760">Weekly Sessions</offsets></th><th align="center"><offsets xml_i="26451" xml_f="26473" txt_i="18760" txt_f="18782">Duration (min/session)</offsets></th><th align="center"><offsets xml_i="26497" xml_f="26515" txt_i="18782" txt_f="18800">Intensity (% of VO</offsets><sub><offsets xml_i="26520" xml_f="26525" txt_i="18800" txt_f="18805">2peak</offsets></sub><offsets xml_i="26531" xml_f="26532" txt_i="18805" txt_f="18806">)</offsets></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="26578" xml_f="26590" txt_i="18806" txt_f="18818">Introductory</offsets></td><td align="center"><offsets xml_i="26614" xml_f="26617" txt_i="18819" txt_f="18822">0-4</offsets></td><td align="center"><offsets xml_i="26641" xml_f="26644" txt_i="18823" txt_f="18826">2-3</offsets></td><td align="center"><offsets xml_i="26668" xml_f="26673" txt_i="18827" txt_f="18832">15-25</offsets></td><td align="center"><offsets xml_i="26697" xml_f="26702" txt_i="18833" txt_f="18838">50-60</offsets></td></tr><tr><td align="left"><offsets xml_i="26733" xml_f="26745" txt_i="18839" txt_f="18851">Intermediate</offsets></td><td align="center"><offsets xml_i="26769" xml_f="26772" txt_i="18852" txt_f="18855">5-8</offsets></td><td align="center"><offsets xml_i="26796" xml_f="26797" txt_i="18856" txt_f="18857">3</offsets></td><td align="center"><offsets xml_i="26821" xml_f="26826" txt_i="18858" txt_f="18863">20-30</offsets></td><td align="center"><offsets xml_i="26850" xml_f="26855" txt_i="18864" txt_f="18869">60-70</offsets></td></tr><tr><td align="left"><offsets xml_i="26886" xml_f="26897" txt_i="18870" txt_f="18881">Maintenance</offsets></td><td align="center"><offsets xml_i="26921" xml_f="26925" txt_i="18882" txt_f="18886">9-16</offsets></td><td align="center"><offsets xml_i="26949" xml_f="26950" txt_i="18887" txt_f="18888">3</offsets></td><td align="center"><offsets xml_i="26974" xml_f="26979" txt_i="18889" txt_f="18894">25-45</offsets></td><td align="center"><offsets xml_i="27003" xml_f="27006" txt_i="18895" txt_f="18898">≥70</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="27052" xml_f="27187" txt_i="18899" txt_f="19034">*Weeks intervals shown are goals and may vary for individual patients; All exercise sessions must be performed in a supervised setting.</offsets></p></table-wrap-foot></table-wrap></sec><sec><title><offsets xml_i="27240" xml_f="27278" txt_i="19036" txt_f="19074">Study Arm 2: Resistance Training Alone</offsets></title><p><offsets xml_i="27289" xml_f="27384" txt_i="19075" txt_f="19170">Resistance training will be prescribed according the ASCM guidelines and aimed at increasing VO</offsets><sub><offsets xml_i="27389" xml_f="27394" txt_i="19170" txt_f="19175">2peak</offsets></sub><offsets xml_i="27400" xml_f="27588" txt_i="19175" txt_f="19363">. The ultimate goal for resistance training alone is 3 resistance training sessions/week at an intensity above 60% to 80% of one-repetition maximum (1-RM) for 30-60 minutes/session (Table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="27620" xml_f="27621" txt_i="19363" txt_f="19364">3</offsets></xref><offsets xml_i="27628" xml_f="27888" txt_i="19364" txt_f="19624">). Resistance training will be performed on stationary weight machines (i.e., no free weights). Patients will be progressively trained to perform three sets of 8 to 12 repetitions of 8 resistance exercise alternating between lower and upper body muscle groups.</offsets></p><table-wrap id="T3" position="float"><label><offsets xml_i="27936" xml_f="27943" txt_i="19625" txt_f="19632">Table 3</offsets></label><caption><p><offsets xml_i="27963" xml_f="27996" txt_i="19632" txt_f="19665">Resistance Training Alone Program</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th></th><th align="center" colspan="4"><offsets xml_i="28107" xml_f="28137" txt_i="19666" txt_f="19696">Supervised Resistance Training</offsets></th></tr><tr><th></th><th colspan="5"><hr></hr></th></tr><tr><th align="left"><offsets xml_i="28216" xml_f="28230" txt_i="19696" txt_f="19710">Training Phase</offsets></th><th align="center"><offsets xml_i="28254" xml_f="28258" txt_i="19710" txt_f="19714">Week</offsets></th><th align="center"><offsets xml_i="28282" xml_f="28297" txt_i="19714" txt_f="19729">Weekly Sessions</offsets></th><th align="center"><offsets xml_i="28321" xml_f="28328" txt_i="19729" txt_f="19736">Sets, n</offsets></th><th align="center"><offsets xml_i="28352" xml_f="28366" txt_i="19736" txt_f="19750">Repetitions, n</offsets></th><th align="center"><offsets xml_i="28390" xml_f="28417" txt_i="19750" txt_f="19777">Weight, maximum repetitions</offsets></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="28463" xml_f="28475" txt_i="19777" txt_f="19789">Introductory</offsets></td><td align="center"><offsets xml_i="28499" xml_f="28502" txt_i="19790" txt_f="19793">0-4</offsets></td><td align="center"><offsets xml_i="28526" xml_f="28529" txt_i="19794" txt_f="19797">2-3</offsets></td><td align="center"><offsets xml_i="28553" xml_f="28556" txt_i="19798" txt_f="19801">1-2</offsets></td><td align="center"><offsets xml_i="28580" xml_f="28584" txt_i="19802" txt_f="19806">8-12</offsets></td><td align="center"><offsets xml_i="28608" xml_f="28610" txt_i="19807" txt_f="19809">12</offsets></td></tr><tr><td align="left"><offsets xml_i="28641" xml_f="28653" txt_i="19810" txt_f="19822">Intermediate</offsets></td><td align="center"><offsets xml_i="28677" xml_f="28680" txt_i="19823" txt_f="19826">5-8</offsets></td><td align="center"><offsets xml_i="28704" xml_f="28705" txt_i="19827" txt_f="19828">3</offsets></td><td align="center"><offsets xml_i="28729" xml_f="28732" txt_i="19829" txt_f="19832">2-3</offsets></td><td align="center"><offsets xml_i="28756" xml_f="28760" txt_i="19833" txt_f="19837">8-12</offsets></td><td align="center"><offsets xml_i="28784" xml_f="28786" txt_i="19838" txt_f="19840">12</offsets></td></tr><tr><td align="left"><offsets xml_i="28817" xml_f="28828" txt_i="19841" txt_f="19852">Maintenance</offsets></td><td align="center"><offsets xml_i="28852" xml_f="28856" txt_i="19853" txt_f="19857">9-16</offsets></td><td align="center"><offsets xml_i="28880" xml_f="28881" txt_i="19858" txt_f="19859">3</offsets></td><td align="center"><offsets xml_i="28905" xml_f="28906" txt_i="19860" txt_f="19861">3</offsets></td><td align="center"><offsets xml_i="28930" xml_f="28934" txt_i="19862" txt_f="19866">8-10</offsets></td><td align="center"><offsets xml_i="28958" xml_f="28960" txt_i="19867" txt_f="19869">10</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="29006" xml_f="29141" txt_i="19870" txt_f="20005">*Weeks intervals shown are goals and may vary for individual patients; All exercise sessions must be performed in a supervised setting.</offsets></p></table-wrap-foot></table-wrap></sec><sec><title><offsets xml_i="29194" xml_f="29247" txt_i="20007" txt_f="20060">Study Arm 3: Combined Aerobic and Resistance Training</offsets></title><p><offsets xml_i="29258" xml_f="29374" txt_i="20061" txt_f="20177">Combined aerobic and resistance training will be prescribed according the ASCM guidelines and aimed at increasing VO</offsets><sub><offsets xml_i="29379" xml_f="29384" txt_i="20177" txt_f="20182">2peak</offsets></sub><offsets xml_i="29390" xml_f="29488" txt_i="20182" txt_f="20280">. The ultimate goal will be three combined exercise sessions per week at an intensity above 60% VO</offsets><sub><offsets xml_i="29493" xml_f="29499" txt_i="20280" txt_f="20286">2peak </offsets></sub><offsets xml_i="29505" xml_f="29670" txt_i="20286" txt_f="20451">and above 60% 1-RM for aerobic and resistance training, respectively for 30-60 minutes/session. The general design of the combined intervention is provided in Table </offsets><xref ref-type="table" rid="T4"><offsets xml_i="29702" xml_f="29703" txt_i="20451" txt_f="20452">4</offsets></xref><offsets xml_i="29710" xml_f="30020" txt_i="20452" txt_f="20762"> and follows similar intensities to the single modality training. In this arm, the duration of aerobic training and resistance training will not be added together but rather the exercise prescription is designed to exploit the complementary properties of aerobic and resistance training to optimally improve VO</offsets><sub><offsets xml_i="30025" xml_f="30030" txt_i="20762" txt_f="20767">2peak</offsets></sub><offsets xml_i="30036" xml_f="30429" txt_i="20767" txt_f="21160">. The prescription will be balanced to ensure that on days when aerobic training is prescribed at a high-intensity, resistance training (on the same day) will be conducted at a lower (easy) intensity and vice versa. This approach will optimize the desired adaptations without causing excessive fatigue and will help avoid potential interference effects between aerobic and resistance training.</offsets></p><table-wrap id="T4" position="float"><label><offsets xml_i="30477" xml_f="30484" txt_i="21161" txt_f="21168">Table 4</offsets></label><caption><p><offsets xml_i="30504" xml_f="30552" txt_i="21168" txt_f="21216">Combined Aerobic and Resistance Training Program</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th></th><th align="center" colspan="3"><offsets xml_i="30663" xml_f="30679" txt_i="21217" txt_f="21233">Aerobic Training</offsets></th><th align="center" colspan="4"><offsets xml_i="30715" xml_f="30734" txt_i="21233" txt_f="21252">Resistance Training</offsets></th></tr><tr><th></th><th colspan="8"><hr></hr></th></tr><tr><th align="left"><offsets xml_i="30813" xml_f="30827" txt_i="21252" txt_f="21266">Training Phase</offsets></th><th align="center"><offsets xml_i="30851" xml_f="30854" txt_i="21266" txt_f="21269">Wk*</offsets></th><th align="center"><offsets xml_i="30878" xml_f="30893" txt_i="21269" txt_f="21284">Weekly Sessions</offsets></th><th align="center"><offsets xml_i="30917" xml_f="30939" txt_i="21284" txt_f="21306">Duration (min/session)</offsets></th><th align="center"><offsets xml_i="30963" xml_f="30978" txt_i="21306" txt_f="21321">Intensity of VO</offsets><sub><offsets xml_i="30983" xml_f="30988" txt_i="21321" txt_f="21326">2peak</offsets></sub></th><th align="center"><offsets xml_i="31018" xml_f="31040" txt_i="21326" txt_f="21348">Duration (min/session)</offsets></th><th align="center"><offsets xml_i="31064" xml_f="31071" txt_i="21348" txt_f="21355">Sets, n</offsets></th><th align="center"><offsets xml_i="31095" xml_f="31109" txt_i="21355" txt_f="21369">Repetitions, n</offsets></th><th align="center"><offsets xml_i="31133" xml_f="31156" txt_i="21369" txt_f="21392">Weight, max repetitions</offsets></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="31202" xml_f="31214" txt_i="21392" txt_f="21404">Introductory</offsets></td><td align="center"><offsets xml_i="31238" xml_f="31241" txt_i="21405" txt_f="21408">0-4</offsets></td><td align="center"><offsets xml_i="31265" xml_f="31266" txt_i="21409" txt_f="21410">2</offsets></td><td align="center"><offsets xml_i="31290" xml_f="31295" txt_i="21411" txt_f="21416">15-25</offsets></td><td align="center"><offsets xml_i="31319" xml_f="31324" txt_i="21417" txt_f="21422">50-60</offsets></td><td align="center"><offsets xml_i="31348" xml_f="31353" txt_i="21423" txt_f="21428">15-20</offsets></td><td align="center"><offsets xml_i="31377" xml_f="31378" txt_i="21429" txt_f="21430">1</offsets></td><td align="center"><offsets xml_i="31402" xml_f="31406" txt_i="21431" txt_f="21435">8-12</offsets></td><td align="center"><offsets xml_i="31430" xml_f="31432" txt_i="21436" txt_f="21438">12</offsets></td></tr><tr><td align="left"><offsets xml_i="31463" xml_f="31475" txt_i="21439" txt_f="21451">Intermediate</offsets></td><td align="center"><offsets xml_i="31499" xml_f="31502" txt_i="21452" txt_f="21455">5-9</offsets></td><td align="center"><offsets xml_i="31526" xml_f="31527" txt_i="21456" txt_f="21457">3</offsets></td><td align="center"><offsets xml_i="31551" xml_f="31556" txt_i="21458" txt_f="21463">20-30</offsets></td><td align="center"><offsets xml_i="31580" xml_f="31586" txt_i="21464" txt_f="21467">&gt;70</offsets></td><td align="center"><offsets xml_i="31610" xml_f="31613" txt_i="21468" txt_f="21471">~25</offsets></td><td align="center"><offsets xml_i="31637" xml_f="31638" txt_i="21472" txt_f="21473">2</offsets></td><td align="center"><offsets xml_i="31662" xml_f="31666" txt_i="21474" txt_f="21478">8-12</offsets></td><td align="center"><offsets xml_i="31690" xml_f="31692" txt_i="21479" txt_f="21481">12</offsets></td></tr><tr><td align="left"><offsets xml_i="31723" xml_f="31734" txt_i="21482" txt_f="21493">Maintenance</offsets></td><td align="center"><offsets xml_i="31758" xml_f="31763" txt_i="21494" txt_f="21499">10-24</offsets></td><td align="center"><offsets xml_i="31787" xml_f="31788" txt_i="21500" txt_f="21501">3</offsets></td><td align="center"><offsets xml_i="31812" xml_f="31817" txt_i="21502" txt_f="21507">30-45</offsets></td><td align="center"><offsets xml_i="31841" xml_f="31847" txt_i="21508" txt_f="21511">&gt;70</offsets></td><td align="center"><offsets xml_i="31871" xml_f="31874" txt_i="21512" txt_f="21515">~30</offsets></td><td align="center"><offsets xml_i="31898" xml_f="31899" txt_i="21516" txt_f="21517">2</offsets></td><td align="center"><offsets xml_i="31923" xml_f="31927" txt_i="21518" txt_f="21522">8-10</offsets></td><td align="center"><offsets xml_i="31951" xml_f="31953" txt_i="21523" txt_f="21525">10</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="31999" xml_f="32133" txt_i="21526" txt_f="21660">*Week intervals shown are goals and may vary for individual patients. All exercise sessions must be performed in a supervised setting.</offsets></p></table-wrap-foot></table-wrap></sec></sec><sec><title><offsets xml_i="32192" xml_f="32229" txt_i="21663" txt_f="21700">Attention Control Group (Study Arm 4)</offsets></title><p><offsets xml_i="32240" xml_f="32566" txt_i="21701" txt_f="22027">Subjects assigned to the attention-control group will perform supervised progressive stretching matched to the exercise interventions in terms of program length (i.e., 16 weeks), social interaction (participants will receive one-on-one instruction), and duration (30-45 mins/session). The progressive stretching program will b</offsets><xref ref-type="table" rid="T5"><offsets xml_i="32598" xml_f="32599" txt_i="22027" txt_f="22028">5</offsets></xref><offsets xml_i="32606" xml_f="32820" txt_i="22028" txt_f="22242">). Stretching will be performed supine on stretching mats (i.e., no machines). Patients will be progressively trained to perform 8 stretching exercises alternating between lower and upper body muscle groups/joints.</offsets></p><table-wrap id="T5" position="float"><label><offsets xml_i="32868" xml_f="32875" txt_i="22243" txt_f="22250">Table 5</offsets></label><caption><p><offsets xml_i="32895" xml_f="32920" txt_i="22250" txt_f="22275">Attention Control Program</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th></th><th align="center" colspan="3"><offsets xml_i="33031" xml_f="33058" txt_i="22276" txt_f="22303">Supervised Aerobic Training</offsets></th></tr><tr><th></th><th colspan="4"><hr></hr></th></tr><tr><th align="left"><offsets xml_i="33137" xml_f="33151" txt_i="22303" txt_f="22317">Training Phase</offsets></th><th align="center"><offsets xml_i="33175" xml_f="33179" txt_i="22317" txt_f="22321">Week</offsets></th><th align="center"><offsets xml_i="33203" xml_f="33218" txt_i="22321" txt_f="22336">Weekly Sessions</offsets></th><th align="center"><offsets xml_i="33242" xml_f="33264" txt_i="22336" txt_f="22358">Duration (min/session)</offsets></th><th align="center"><offsets xml_i="33288" xml_f="33319" txt_i="22358" txt_f="22389">Duration of each Stretch (mins)</offsets></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="33365" xml_f="33377" txt_i="22389" txt_f="22401">Introductory</offsets></td><td align="center"><offsets xml_i="33401" xml_f="33404" txt_i="22402" txt_f="22405">0-4</offsets></td><td align="center"><offsets xml_i="33428" xml_f="33431" txt_i="22406" txt_f="22409">2-3</offsets></td><td align="center"><offsets xml_i="33455" xml_f="33460" txt_i="22410" txt_f="22415">15-25</offsets></td><td align="center"><offsets xml_i="33484" xml_f="33487" txt_i="22416" txt_f="22419">1-2</offsets></td></tr><tr><td align="left"><offsets xml_i="33518" xml_f="33530" txt_i="22420" txt_f="22432">Intermediate</offsets></td><td align="center"><offsets xml_i="33554" xml_f="33557" txt_i="22433" txt_f="22436">5-8</offsets></td><td align="center"><offsets xml_i="33581" xml_f="33582" txt_i="22437" txt_f="22438">3</offsets></td><td align="center"><offsets xml_i="33606" xml_f="33611" txt_i="22439" txt_f="22444">20-30</offsets></td><td align="center"><offsets xml_i="33635" xml_f="33638" txt_i="22445" txt_f="22448">2-5</offsets></td></tr><tr><td align="left"><offsets xml_i="33669" xml_f="33680" txt_i="22449" txt_f="22460">Maintenance</offsets></td><td align="center"><offsets xml_i="33704" xml_f="33708" txt_i="22461" txt_f="22465">9-16</offsets></td><td align="center"><offsets xml_i="33732" xml_f="33733" txt_i="22466" txt_f="22467">3</offsets></td><td align="center"><offsets xml_i="33757" xml_f="33762" txt_i="22468" txt_f="22473">25-45</offsets></td><td align="center"><offsets xml_i="33786" xml_f="33788" txt_i="22474" txt_f="22476">≥5</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="33834" xml_f="33969" txt_i="22477" txt_f="22612">*Weeks intervals shown are goals and may vary for individual patients; All exercise sessions must be performed in a supervised setting.</offsets></p></table-wrap-foot></table-wrap></sec><sec><title><offsets xml_i="34022" xml_f="34046" txt_i="22614" txt_f="22638">Adherence Considerations</offsets></title><p><offsets xml_i="34057" xml_f="35033" txt_i="22639" txt_f="23615">To maximize adherence, several strategies will be employed including individualized attention at the intervention sessions, telephone calls following missed sessions, individuals meetings to outline goals and providing feedback on study progress. In addition, participants will be asked to perform 3 supervised exercise/stretching sessions per week over a 7-day period, and will be allowed to make-up missed sessions within the 16-week study period. Also, participants will be allowed to schedule supervised exercise training sessions at anytime from 7 am to 7 pm. This degree of scheduling flexibility allows participants to perform exercise training sessions at a convenient time and work around other competing demands such as medical appointments, work, and family commitments. Finally, the study team, consisting of the PI, the exercise physiologist and study coordinator, will also meet on a weekly basis to review each participant's adherence with weekly program goals.</offsets></p></sec><sec><title><offsets xml_i="35055" xml_f="35086" txt_i="23617" txt_f="23648">Study Endpoints and Assessments</offsets></title><p><offsets xml_i="35097" xml_f="35103" txt_i="23649" txt_f="23655">Table </offsets><xref ref-type="table" rid="T6"><offsets xml_i="35135" xml_f="35136" txt_i="23655" txt_f="23656">6</offsets></xref><offsets xml_i="35143" xml_f="35296" txt_i="23656" txt_f="23809"> outlines the study assessment schedule while a brief description of study endpoints and endpoint assessments including sub-studies is provided in Table </offsets><xref ref-type="table" rid="T7"><offsets xml_i="35328" xml_f="35329" txt_i="23809" txt_f="23810">7</offsets></xref><offsets xml_i="35336" xml_f="35337" txt_i="23810" txt_f="23811">.</offsets></p><table-wrap id="T6" position="float"><label><offsets xml_i="35385" xml_f="35392" txt_i="23812" txt_f="23819">Table 6</offsets></label><caption><p><offsets xml_i="35412" xml_f="35437" txt_i="23819" txt_f="23844">Study Assessment Schedule</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th></th><th></th><th align="center"><offsets xml_i="35545" xml_f="35553" txt_i="23845" txt_f="23853">Baseline</offsets></th><th></th><th></th><th align="center" colspan="2"><offsets xml_i="35607" xml_f="35634" txt_i="23853" txt_f="23880">Postintervention (16 weeks)</offsets></th></tr><tr><th align="left"><offsets xml_i="35665" xml_f="35675" txt_i="23880" txt_f="23890">Assessment</offsets></th><th align="center"><offsets xml_i="35699" xml_f="35708" txt_i="23890" txt_f="23899">Screening</offsets></th><th align="center"><offsets xml_i="35732" xml_f="35737" txt_i="23899" txt_f="23904">Day 0</offsets></th><th align="center"><offsets xml_i="35761" xml_f="35766" txt_i="23904" txt_f="23909">Day 1</offsets></th><th align="center"><offsets xml_i="35790" xml_f="35795" txt_i="23909" txt_f="23914">Day 2</offsets></th><th align="center"><offsets xml_i="35819" xml_f="35826" txt_i="23914" txt_f="23921">Day 3-5</offsets></th><th align="center"><offsets xml_i="35850" xml_f="35857" txt_i="23921" txt_f="23928">Day 112</offsets></th><th align="center"><offsets xml_i="35881" xml_f="35888" txt_i="23928" txt_f="23935">Day 113</offsets></th></tr></thead><tbody><tr><td align="left"><offsets xml_i="35934" xml_f="35946" txt_i="23935" txt_f="23947">Chart Review</offsets></td><td align="center"><offsets xml_i="35970" xml_f="35971" txt_i="23948" txt_f="23949">x</offsets></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="36056" xml_f="36074" txt_i="23956" txt_f="23974">Patient Approached</offsets></td><td align="center"><offsets xml_i="36098" xml_f="36099" txt_i="23975" txt_f="23976">x</offsets></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="36184" xml_f="36200" txt_i="23983" txt_f="23999">Informed Consent</offsets></td><td align="center"><offsets xml_i="36224" xml_f="36225" txt_i="24000" txt_f="24001">x</offsets></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><underline><offsets xml_i="36321" xml_f="36334" txt_i="24008" txt_f="24021">Day 1 Testing</offsets></underline></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="36440" xml_f="36451" txt_i="24029" txt_f="24040"> Blood draw</offsets></td><td></td><td align="center"><offsets xml_i="36484" xml_f="36485" txt_i="24042" txt_f="24043">x</offsets></td><td></td><td></td><td></td><td align="center"><offsets xml_i="36536" xml_f="36537" txt_i="24047" txt_f="24048">x</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="36577" xml_f="36594" txt_i="24050" txt_f="24067"> Body Composition</offsets></td><td></td><td align="center"><offsets xml_i="36627" xml_f="36628" txt_i="24069" txt_f="24070">x</offsets></td><td></td><td></td><td></td><td align="center"><offsets xml_i="36679" xml_f="36680" txt_i="24074" txt_f="24075">x</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="36720" xml_f="36739" txt_i="24077" txt_f="24096"> Pulmonary Function</offsets></td><td></td><td align="center"><offsets xml_i="36772" xml_f="36773" txt_i="24098" txt_f="24099">x</offsets></td><td></td><td></td><td></td><td align="center"><offsets xml_i="36824" xml_f="36825" txt_i="24103" txt_f="24104">x</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="36865" xml_f="36870" txt_i="24106" txt_f="24111"> CPET</offsets></td><td></td><td align="center"><offsets xml_i="36903" xml_f="36904" txt_i="24113" txt_f="24114">x</offsets></td><td></td><td></td><td></td><td align="center"><offsets xml_i="36955" xml_f="36956" txt_i="24118" txt_f="24119">x</offsets></td><td></td></tr><tr><td align="left"><offsets xml_i="36996" xml_f="37011" txt_i="24121" txt_f="24136"> Echocardiogram</offsets></td><td></td><td align="center"><offsets xml_i="37044" xml_f="37045" txt_i="24138" txt_f="24139">x</offsets></td><td></td><td></td><td></td><td align="center"><offsets xml_i="37096" xml_f="37097" txt_i="24143" txt_f="24144">x</offsets></td><td></td></tr><tr><td align="left"><underline><offsets xml_i="37148" xml_f="37161" txt_i="24146" txt_f="24159">Day 2 Testing</offsets></underline></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="37267" xml_f="37284" txt_i="24167" txt_f="24184"> Strength testing</offsets></td><td></td><td></td><td align="center"><offsets xml_i="37326" xml_f="37327" txt_i="24187" txt_f="24188">x</offsets></td><td></td><td></td><td></td><td align="center"><offsets xml_i="37378" xml_f="37379" txt_i="24192" txt_f="24193">x</offsets></td></tr><tr><td align="left"><offsets xml_i="37410" xml_f="37424" txt_i="24194" txt_f="24208"> Muscle biopsy</offsets></td><td></td><td></td><td align="center"><offsets xml_i="37466" xml_f="37467" txt_i="24211" txt_f="24212">x</offsets></td><td></td><td></td><td></td><td align="center"><offsets xml_i="37518" xml_f="37519" txt_i="24216" txt_f="24217">x</offsets></td></tr><tr><td align="left"><underline><offsets xml_i="37561" xml_f="37574" txt_i="24218" txt_f="24231">Day 3 Testing</offsets></underline></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="37680" xml_f="37692" txt_i="24239" txt_f="24251"> Repeat CPET</offsets></td><td></td><td></td><td></td><td align="center"><offsets xml_i="37743" xml_f="37744" txt_i="24255" txt_f="24256">x</offsets></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="37802" xml_f="37816" txt_i="24260" txt_f="24274"> Randomization</offsets></td><td></td><td></td><td></td><td align="center"><offsets xml_i="37867" xml_f="37868" txt_i="24278" txt_f="24279">x</offsets></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="37926" xml_f="37950" txt_i="24283" txt_f="24307"> Intervention initiation</offsets></td><td></td><td></td><td></td><td></td><td align="center"><offsets xml_i="38010" xml_f="38011" txt_i="24312" txt_f="24313">x</offsets></td><td></td><td></td></tr></tbody></table></table-wrap><table-wrap id="T7" position="float"><label><offsets xml_i="38112" xml_f="38119" txt_i="24316" txt_f="24323">Table 7</offsets></label><caption><p><offsets xml_i="38139" xml_f="38173" txt_i="24323" txt_f="24357">Study Measurements and Sub-Studies</offsets></p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left"><offsets xml_i="38252" xml_f="38283" txt_i="24358" txt_f="24389">Physical measurements and tests</offsets></td></tr><tr><td align="left"><offsets xml_i="38314" xml_f="38350" txt_i="24390" txt_f="24426"> Height, weight, and body mass index</offsets></td></tr><tr><td align="left"><offsets xml_i="38381" xml_f="38398" txt_i="24427" txt_f="24444"> Body composition</offsets></td></tr><tr><td align="left"><offsets xml_i="38429" xml_f="38461" txt_i="24445" txt_f="24477"> Resting and exercise heart rate</offsets></td></tr><tr><td align="left"><offsets xml_i="38492" xml_f="38528" txt_i="24478" txt_f="24514"> Resting and exercise blood pressure</offsets></td></tr><tr><td align="left"><offsets xml_i="38559" xml_f="38592" txt_i="24515" txt_f="24548"> Resting and exercise 12-lead ECG</offsets></td></tr><tr><td align="left"><offsets xml_i="38623" xml_f="38662" txt_i="24549" txt_f="24588"> Peak and submaximal oxygen consumption</offsets></td></tr><tr><td align="left"><offsets xml_i="38693" xml_f="38715" txt_i="24589" txt_f="24611"> Ventilatory threshold</offsets></td></tr><tr><td></td></tr><tr><td align="left"><offsets xml_i="38764" xml_f="38802" txt_i="24613" txt_f="24651">Mechanistic physiological measurements</offsets></td></tr><tr><td align="left"><offsets xml_i="38833" xml_f="38869" txt_i="24652" txt_f="24688"> Resting and exercise echocardiogram</offsets></td></tr><tr><td align="left"><offsets xml_i="38900" xml_f="38994" txt_i="24689" txt_f="24783"> Skeletal muscle function (fiber type distribution, oxidative capacity, and muscular strength)</offsets></td></tr><tr><td align="left"><offsets xml_i="39025" xml_f="39044" txt_i="24784" txt_f="24803"> Pulmonary function</offsets></td></tr><tr><td align="left"><offsets xml_i="39075" xml_f="39100" txt_i="24804" txt_f="24829"> Hemoglobin concentration</offsets></td></tr><tr><td align="left"><offsets xml_i="39131" xml_f="39170" txt_i="24830" txt_f="24869"> Resting and exercise oxygen saturation</offsets></td></tr><tr><td align="left"><offsets xml_i="39201" xml_f="39311" txt_i="24870" txt_f="24980"> Each intervention (exercise or attention control) session: heart rate, blood pressure, oxygen saturation, RPE</offsets></td></tr><tr><td></td></tr><tr><td align="left"><offsets xml_i="39360" xml_f="39407" txt_i="24982" txt_f="25029">Patient-reported outcomes (questionnaire-based)</offsets></td></tr><tr><td align="left"><offsets xml_i="39438" xml_f="39450" txt_i="25030" txt_f="25042"> Medications</offsets></td></tr><tr><td align="left"><offsets xml_i="39481" xml_f="39497" txt_i="25043" txt_f="25059"> Quality of life</offsets></td></tr><tr><td align="left"><offsets xml_i="39528" xml_f="39536" txt_i="25060" txt_f="25068"> Fatigue</offsets></td></tr><tr><td align="left"><offsets xml_i="39567" xml_f="39575" txt_i="25069" txt_f="25077"> Dyspnea</offsets></td></tr><tr><td align="left"><offsets xml_i="39606" xml_f="39617" txt_i="25078" txt_f="25089"> Depression</offsets></td></tr><tr><td align="left"><offsets xml_i="39648" xml_f="39725" txt_i="25090" txt_f="25167"> Adverse events (Common Terminology Criteria for Adverse Events; CTCAE v.4.0)</offsets></td></tr><tr><td></td></tr><tr><td align="left"><offsets xml_i="39774" xml_f="39784" txt_i="25169" txt_f="25179">Substudies</offsets></td></tr><tr><td align="left"><offsets xml_i="39815" xml_f="39875" txt_i="25180" txt_f="25240"> Genetic studies to examine differences to exercise stimulus</offsets></td></tr><tr><td align="left"><offsets xml_i="39906" xml_f="39939" txt_i="25241" txt_f="25274"> Predictors of exercise adherence</offsets></td></tr><tr><td align="left"><offsets xml_i="39970" xml_f="40043" txt_i="25275" txt_f="25348"> Pilot studies for exercise-induced changes in peripheral gene expression</offsets></td></tr></tbody></table></table-wrap><sec><title><offsets xml_i="40094" xml_f="40110" txt_i="25349" txt_f="25365">Primary Endpoint</offsets></title><p><italic><offsets xml_i="40129" xml_f="40131" txt_i="25366" txt_f="25368">VO</offsets></italic><sub><offsets xml_i="40145" xml_f="40151" txt_i="25368" txt_f="25374">2peak </offsets></sub><offsets xml_i="40157" xml_f="40269" txt_i="25374" txt_f="25486">will be evaluated using a physician-supervised incremental cycle ergometer test with 12-lead ECG monitoring (Mac</offsets><sup><offsets xml_i="40274" xml_f="40276" txt_i="25486" txt_f="25488">® </offsets></sup><offsets xml_i="40282" xml_f="40660" txt_i="25488" txt_f="25866">5000, GE Healthcare) will be performed by ACSM-certified exercise physiologists blinded to the patient's randomization group. Expired gases will be analyzed continuously by a metabolic measurement system (ParvoMedics TrueMax, Sandy, UT). Subjects will begin pedaling at 20 Watts for one minute and is increased 5 to 20 Watts every minute until exhaustion or a symptom-limited VO</offsets><sub><offsets xml_i="40665" xml_f="40671" txt_i="25866" txt_f="25872">2peak </offsets></sub><offsets xml_i="40677" xml_f="40771" txt_i="25872" txt_f="25966">is achieved. This protocol has been previously demonstrated to be appropriate for measuring VO</offsets><sub><offsets xml_i="40776" xml_f="40782" txt_i="25966" txt_f="25972">2peak </offsets></sub><offsets xml_i="40788" xml_f="40830" txt_i="25972" txt_f="26014">in our prior studies among NSCLC patients[</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="40862" xml_f="40864" txt_i="26014" txt_f="26016">18</offsets></xref><offsets xml_i="40871" xml_f="40872" txt_i="26016" txt_f="26017">,</offsets><xref ref-type="bibr" rid="B36"><offsets xml_i="40904" xml_f="40906" txt_i="26017" txt_f="26019">36</offsets></xref><offsets xml_i="40913" xml_f="40914" txt_i="26019" txt_f="26020">-</offsets><xref ref-type="bibr" rid="B38"><offsets xml_i="40946" xml_f="40948" txt_i="26020" txt_f="26022">38</offsets></xref><offsets xml_i="40955" xml_f="41024" txt_i="26022" txt_f="26091">]. Exercise will be terminated if any ECG abnormalities are observed.</offsets></p></sec></sec><sec><title><offsets xml_i="41052" xml_f="41071" txt_i="26094" txt_f="26113">Secondary Endpoints</offsets></title><p><bold><offsets xml_i="41088" xml_f="41114" txt_i="26114" txt_f="26140">Patient Reported Outcomes </offsets></bold><offsets xml_i="41121" xml_f="41173" txt_i="26140" txt_f="26192">will include QOL, fatigue, dyspnea, and depression. </offsets><italic><offsets xml_i="41181" xml_f="41185" txt_i="26192" txt_f="26196">QOL </offsets></italic><offsets xml_i="41194" xml_f="41365" txt_i="26196" txt_f="26367">will be assessed using the Functional Assessment of Cancer Therapy - Lung (FACT-L) scale developed for the assessment of patient symptoms and QOL in lung cancer patients [</offsets><xref ref-type="bibr" rid="B39"><offsets xml_i="41397" xml_f="41399" txt_i="26367" txt_f="26369">39</offsets></xref><offsets xml_i="41406" xml_f="41658" txt_i="26369" txt_f="26621">]. The FACT-L contains four subscales for physical (7-items), functional (7-items), emotional (6-items), social/family (7-items) well-being plus a lung cancer specific subscale (15-items) which will be summed to obtain the FACT-L score (all 42 items). </offsets><italic><offsets xml_i="41666" xml_f="41674" txt_i="26621" txt_f="26629">Fatigue </offsets></italic><offsets xml_i="41683" xml_f="41786" txt_i="26629" txt_f="26732">will be assessed using the 13-item FACT-fatigue scale for the assessment of fatigue in cancer patients[</offsets><xref ref-type="bibr" rid="B40"><offsets xml_i="41818" xml_f="41820" txt_i="26732" txt_f="26734">40</offsets></xref><offsets xml_i="41827" xml_f="41830" txt_i="26734" txt_f="26737">]. </offsets><italic><offsets xml_i="41838" xml_f="41846" txt_i="26737" txt_f="26745">Dyspnea </offsets></italic><offsets xml_i="41855" xml_f="41909" txt_i="26745" txt_f="26799">will be assessed using the Cancer Dyspnea Scale (CDS)[</offsets><xref ref-type="bibr" rid="B41"><offsets xml_i="41941" xml_f="41943" txt_i="26799" txt_f="26801">41</offsets></xref><offsets xml_i="41950" xml_f="42210" txt_i="26801" txt_f="27061">]. The CDS is a 12-item scale comprised of three factors (sense of sense/sense of anxiety/sense of discomfort). This instrument has been demonstrated to be a brief, valid, and feasible scale for assessing cancer-related dyspnea among inoperable NSCLC patients[</offsets><xref ref-type="bibr" rid="B42"><offsets xml_i="42242" xml_f="42244" txt_i="27061" txt_f="27063">42</offsets></xref><offsets xml_i="42251" xml_f="42252" txt_i="27063" txt_f="27064">,</offsets><xref ref-type="bibr" rid="B43"><offsets xml_i="42284" xml_f="42286" txt_i="27064" txt_f="27066">43</offsets></xref><offsets xml_i="42293" xml_f="42305" txt_i="27066" txt_f="27078">]. Finally, </offsets><italic><offsets xml_i="42313" xml_f="42324" txt_i="27078" txt_f="27089">depression </offsets></italic><offsets xml_i="42333" xml_f="42418" txt_i="27089" txt_f="27174">will be assessed using the Center for Epidemiologic Studies Depression scale (CES-D)[</offsets><xref ref-type="bibr" rid="B44"><offsets xml_i="42450" xml_f="42452" txt_i="27174" txt_f="27176">44</offsets></xref><offsets xml_i="42459" xml_f="42623" txt_i="27176" txt_f="27340">]. We have found these instruments to be reliable, valid, responsive, brief, and easy to administer in our on-going study and prior reports in lung cancer patients.</offsets></p><p><bold><offsets xml_i="42636" xml_f="42664" txt_i="27341" txt_f="27369">Physiologic Mechanisms of VO</offsets><sub><offsets xml_i="42669" xml_f="42675" txt_i="27369" txt_f="27375">2peak </offsets></sub></bold><offsets xml_i="42688" xml_f="42737" txt_i="27375" txt_f="27424">will include pulmonary function, cardiovascular O</offsets><sub><offsets xml_i="42742" xml_f="42744" txt_i="27424" txt_f="27426">2 </offsets></sub><offsets xml_i="42750" xml_f="42790" txt_i="27426" txt_f="27466">delivery, and skeletal muscle function. </offsets><italic><offsets xml_i="42798" xml_f="42817" txt_i="27466" txt_f="27485">Pulmonary Function </offsets></italic><offsets xml_i="42826" xml_f="42884" txt_i="27485" txt_f="27543">will be determined using standard spirometry to assess FEV</offsets><sub><offsets xml_i="42889" xml_f="42890" txt_i="27543" txt_f="27544">1</offsets></sub><offsets xml_i="42896" xml_f="43006" txt_i="27544" txt_f="27654">. All measures will be performed in a sitting position according to the American Thoracic Society guidelines [</offsets><xref ref-type="bibr" rid="B45"><offsets xml_i="43038" xml_f="43040" txt_i="27654" txt_f="27656">45</offsets></xref><offsets xml_i="43047" xml_f="43050" txt_i="27656" txt_f="27659">]. </offsets><italic><offsets xml_i="43058" xml_f="43074" txt_i="27659" txt_f="27675">Cardiovascular O</offsets></italic><sub><offsets xml_i="43088" xml_f="43089" txt_i="27675" txt_f="27676">2</offsets></sub><italic><offsets xml_i="43103" xml_f="43112" txt_i="27676" txt_f="27685">Delivery </offsets></italic><offsets xml_i="43121" xml_f="43143" txt_i="27685" txt_f="27707">will be comprised of: </offsets><italic><offsets xml_i="43151" xml_f="43169" txt_i="27707" txt_f="27725">(1) Cardiac Output</offsets></italic><offsets xml_i="43178" xml_f="43477" txt_i="27725" txt_f="28024">: Left ventricular volumes will be performed with a commercially available ultrasound system (GE Vivid 7 or Philips i33). Apical two- and four- chamber views will be assessed at rest and exercise to determine left ventricular end-diastolic volume and end-systolic volume by modified Simpson's rule [</offsets><xref ref-type="bibr" rid="B46"><offsets xml_i="43509" xml_f="43511" txt_i="28024" txt_f="28026">46</offsets></xref><offsets xml_i="43518" xml_f="43519" txt_i="28026" txt_f="28027">,</offsets><xref ref-type="bibr" rid="B47"><offsets xml_i="43551" xml_f="43553" txt_i="28027" txt_f="28029">47</offsets></xref><offsets xml_i="43560" xml_f="43728" txt_i="28029" txt_f="28197">]. Stroke volume will be calculated as end-diastolic volume minus end-systolic volume. Cardiac output will be calculated by stroke volume multiplied by heart rate, (2) </offsets><italic><offsets xml_i="43736" xml_f="43766" txt_i="28197" txt_f="28227">Hemoglobin (Hb) Concentration </offsets></italic><offsets xml_i="43775" xml_f="43777" txt_i="28227" txt_f="28229">(O</offsets><sub><offsets xml_i="43782" xml_f="43784" txt_i="28229" txt_f="28231">2 </offsets></sub><offsets xml_i="43790" xml_f="44117" txt_i="28231" txt_f="28558">carrying capacity of blood) will be assessed via a venous blood draw according to standard guidelines. Normal range for hemoglobin is ~13 - 18 grams per deciliter for men and 12 - 16 for women. Mean cell Hb (amount of Hb/red blood cell) and platelet count (number of platelets in blood volume) will also be calculated, and (3) </offsets><italic><offsets xml_i="44125" xml_f="44135" txt_i="28558" txt_f="28568">Arterial O</offsets></italic><sub><offsets xml_i="44149" xml_f="44151" txt_i="28568" txt_f="28570">2 </offsets></sub><italic><offsets xml_i="44165" xml_f="44176" txt_i="28570" txt_f="28581">Saturation </offsets></italic><offsets xml_i="44185" xml_f="44381" txt_i="28581" txt_f="28777">will be assessed at rest and continuously during exercise using pulse oximetry (Biox 3700, Ohmeda Medical, Boulder, CO), which provides the most accurate noninvasive assessment of blood arterial O</offsets><sub><offsets xml_i="44386" xml_f="44388" txt_i="28777" txt_f="28779">2 </offsets></sub><offsets xml_i="44394" xml_f="44603" txt_i="28779" txt_f="28988">saturation levels. Pulse oximetry works on the principle of the red and infrared light absorption characteristics of oxygenated and deoxygenated Hb. Normal range is 96% to 100% at sea level for healthy humans.</offsets></p><p><bold><offsets xml_i="44616" xml_f="44641" txt_i="28989" txt_f="29014">Skeletal Muscle Function </offsets></bold><offsets xml_i="44648" xml_f="44675" txt_i="29014" txt_f="29041">will be determined by: (1) </offsets><italic><offsets xml_i="44683" xml_f="44707" txt_i="29041" txt_f="29065">Fiber Type Distribution </offsets></italic><offsets xml_i="44716" xml_f="44824" txt_i="29065" txt_f="29173">will be determined by tissue biopsy of the vastumus laterialis using a modified Bergstrom needle technique [</offsets><xref ref-type="bibr" rid="B48"><offsets xml_i="44856" xml_f="44858" txt_i="29173" txt_f="29175">48</offsets></xref><offsets xml_i="44865" xml_f="45140" txt_i="29175" txt_f="29450">]. Biopsy sites will be first anesthetized with a 2% lidocaine solution. Next, a 0.5 cm incision will be made through the skin and fascia lata. All samples will be prepared immediately by weighing and then dividing the samples for subsequent analysis as previously described[</offsets><xref ref-type="bibr" rid="B48"><offsets xml_i="45172" xml_f="45174" txt_i="29450" txt_f="29452">48</offsets></xref><offsets xml_i="45181" xml_f="45510" txt_i="29452" txt_f="29781">]. A portion will be mounted in cross-section in optimal temperature compound (OCT) media immediately prior to being frozen in isopentane cooled by liquid nitrogen for fiber type determination. Specifically, myosin heavy-chain (MHC) isoforms I, IIa, and IIx will be identified by order of migration as described by Duscha et al [</offsets><xref ref-type="bibr" rid="B48"><offsets xml_i="45542" xml_f="45544" txt_i="29781" txt_f="29783">48</offsets></xref><offsets xml_i="45551" xml_f="45719" txt_i="29783" txt_f="29951">]. Gels will be scanned electronically, and relative proportions of MHC isoform will be measured using NIH image 1.60 for Macintosh and Jandel PeakFit for Windows, (2) </offsets><italic><offsets xml_i="45727" xml_f="45746" txt_i="29951" txt_f="29970">Oxidative Capacity </offsets></italic><offsets xml_i="45755" xml_f="45756" txt_i="29970" txt_f="29971">(</offsets><italic><offsets xml_i="45764" xml_f="45774" txt_i="29971" txt_f="29981">Enzymology</offsets></italic><offsets xml_i="45783" xml_f="45952" txt_i="29981" txt_f="30150">) will be assessed via maximal activities of several oxidative pathways representative of different energy pathways using frozen tissue samples as previously described [</offsets><xref ref-type="bibr" rid="B48"><offsets xml_i="45984" xml_f="45986" txt_i="30150" txt_f="30152">48</offsets></xref><offsets xml_i="45993" xml_f="46234" txt_i="30152" txt_f="30393">]. Phosphofructokinase and succinic dehydrogenase activities will be performed on fresh homogenates while the enzymes malate dehydrogenase and 3-hydoxyl-Co-A dehydrogenase will be performed on the frozen homogenates stored at -80°C, and (3) </offsets><italic><offsets xml_i="46242" xml_f="46284" txt_i="30393" txt_f="30435">Lower Extremity Maximal Muscular Strength </offsets></italic><offsets xml_i="46293" xml_f="46574" txt_i="30435" txt_f="30716">will be assessed as a voluntary one-repetition maximum (1-RM) using the following exercises: (1) leg press, (2) leg extension, and (3) leg curl. These tests will be repeated twice and the heaviest weight lifted while adhering to strict technique and form will be used as the score.</offsets></p></sec><sec><title><offsets xml_i="46596" xml_f="46637" txt_i="30718" txt_f="30759">Tracking and Monitoring of Adverse Events</offsets></title><p><offsets xml_i="46648" xml_f="46973" txt_i="30760" txt_f="31085">Tracking and monitoring of adverse events will be assessed using the following methods: (1) during intervention sessions, all patients will receive one-on-one supervision and all adverse events (e.g., knee pain, back pain) will be recorded on the patient case report form (CRF). In addition, heart rate, blood pressure, and O</offsets><sub><offsets xml_i="46978" xml_f="46980" txt_i="31085" txt_f="31087">2 </offsets></sub><offsets xml_i="46986" xml_f="47841" txt_i="31087" txt_f="31942">saturation will be recorded prior to, during, and following every intervention session, (2) at the beginning of each week, the exercise physiologist will spend the first 10 minutes of every session discussing any potential negative side-effects of the intervention assignment and any injuries that may have occurred. All events will be recorded in the patient CRF, (3) every six months a meeting of all investigators will be scheduled to review and discuss all reported non-serious and serious adverse events for early identification of negative issues and development of solutions. All serious adverse events will be immediately reported to Duke IRB and immediately circulated to all study investigators for appropriate discussion, and (4) early stopping rules in response to a differential higher frequency of adverse events in a particular study group.</offsets></p></sec><sec><title><offsets xml_i="47863" xml_f="47889" txt_i="31944" txt_f="31970">Statistical Considerations</offsets></title><sec><title><offsets xml_i="47909" xml_f="47932" txt_i="31971" txt_f="31994">Sample Size Calculation</offsets></title><p><offsets xml_i="47943" xml_f="48350" txt_i="31995" txt_f="32402">This randomized phase II trial will accrue 160 subjects with postsurgical NSCLC over an accrual period of ~48 months. For each of the primary and secondary endpoints, three separate t-tests will be used to compare each experimental arm to the control arm in mean change across time of the endpoint. For each endpoint, the overall alpha level will be controlled at a two-sided 0.05 by using Holm's procedure[</offsets><xref ref-type="bibr" rid="B49"><offsets xml_i="48382" xml_f="48384" txt_i="32402" txt_f="32404">49</offsets></xref><offsets xml_i="48391" xml_f="48875" txt_i="32404" txt_f="32888">]. That is, Holm's procedure first ranks the three p-values from lowest to highest. The first (lowest) p-value has to be less than 0.05/3 (0.0167) to be significant and permit continuation to the other t-tests. The Holm's procedure continues sequentially in this fashion using alpha levels of 0.05/2 (0.025) and 0.05/1 (0.05) for the remaining two t-tests, respectively. Power for this study is defined as the probability that at least one of the three t-tests of the arm effect on VO</offsets><sub><offsets xml_i="48880" xml_f="48886" txt_i="32888" txt_f="32894">2peak </offsets></sub><offsets xml_i="48892" xml_f="49033" txt_i="32894" txt_f="33035">is significant; in other words, power is the probability that the first of the 3 ordered t-tests are significant. We assume that change in VO</offsets><sub><offsets xml_i="49038" xml_f="49044" txt_i="33035" txt_f="33041">2peak </offsets></sub><offsets xml_i="49050" xml_f="49094" txt_i="33041" txt_f="33085">will have a standard deviation of 3.0 mL.kg.</offsets><sup><offsets xml_i="49099" xml_f="49101" txt_i="33085" txt_f="33087">-1</offsets></sup><offsets xml_i="49107" xml_f="49110" txt_i="33087" txt_f="33090">min</offsets><sup><offsets xml_i="49115" xml_f="49118" txt_i="33090" txt_f="33093">-1 </offsets></sup><offsets xml_i="49124" xml_f="49224" txt_i="33093" txt_f="33193">as observed in our pilot work. Statistical power depends upon the configuration of mean change in VO</offsets><sub><offsets xml_i="49229" xml_f="49235" txt_i="33193" txt_f="33199">2peak </offsets></sub><offsets xml_i="49241" xml_f="49327" txt_i="33199" txt_f="33285">across the 4 arms. Thus, for example, 80% power is obtained when the mean change in VO</offsets><sub><offsets xml_i="49332" xml_f="49338" txt_i="33285" txt_f="33291">2peak </offsets></sub><offsets xml_i="49344" xml_f="49407" txt_i="33291" txt_f="33354">across Arms 1, 2, 3, and 4 is 0.60, 0.60, 2.10, and 0.0 (mL.kg.</offsets><sup><offsets xml_i="49412" xml_f="49414" txt_i="33354" txt_f="33356">-1</offsets></sup><offsets xml_i="49420" xml_f="49423" txt_i="33356" txt_f="33359">min</offsets><sup><offsets xml_i="49428" xml_f="49430" txt_i="33359" txt_f="33361">-1</offsets></sup><offsets xml_i="49436" xml_f="49452" txt_i="33361" txt_f="33377">), respectively.</offsets></p></sec><sec><title><offsets xml_i="49474" xml_f="49487" txt_i="33379" txt_f="33392">Analytic Plan</offsets></title><p><offsets xml_i="49498" xml_f="50037" txt_i="33393" txt_f="33932">The principal analysis of the study endpoints will employ the intention-to-treat (ITT) approach. The ITT analysis will include all randomized participants in their randomly assigned allocation. The intervention group assignment will not be altered based on the participant's adherence to the randomly allocated study arm. Patients who are lost-to-follow-up will be included in all primary and secondary analyses by assuming zero change across time. For the primary analysis, a multiple regression model will be used to regress change in VO</offsets><sub><offsets xml_i="50042" xml_f="50048" txt_i="33932" txt_f="33938">2peak </offsets></sub><offsets xml_i="50054" xml_f="50272" txt_i="33938" txt_f="34156">on study group, the baseline value of the endpoint, and other pertinent baseline variables that may influence change in the study endpoints (e.g., co-morbid conditions/medications, self-reported exercise history, age).</offsets></p></sec></sec></sec><sec><title><offsets xml_i="50306" xml_f="50316" txt_i="34160" txt_f="34170">Discussion</offsets></title><sec><title><offsets xml_i="50336" xml_f="50365" txt_i="34171" txt_f="34200">Methodological Considerations</offsets></title><p><offsets xml_i="50376" xml_f="51197" txt_i="34201" txt_f="35022">Several issues were considered when designing LUNGEVITY. First, was the decision to investigate exercise in patients with operable (early) or inoperable (advanced) NSCLC. The majority of patients (~75%) diagnosed with NSCLC present with inoperable (advanced) disease. From a population health perspective, exercise trials in inoperable disease are likely to greater impact in comparison to those in patients with operable disease. Our decision to target early-stage patients was based on several important factors, primarily, exercise training safety and patient eligibility (recruitment). Inoperable NSCLC patients have poor prognosis and commonly present with significant smoking-related comorbid disease, advanced disease and symptoms, and are heavily treated with aggressive chemotherapy and concurrent radiotherapy [</offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="51229" xml_f="51231" txt_i="35022" txt_f="35024">37</offsets></xref><offsets xml_i="51238" xml_f="51436" txt_i="35024" txt_f="35219">]. As a result, the majority present with KPS scores &lt;70% which may preclude participation in a moderate-intensity exercise training program and increase the risk of an exercise-related adverse [</offsets><xref ref-type="bibr" rid="B37"><offsets xml_i="51468" xml_f="51470" txt_i="35219" txt_f="35221">37</offsets></xref><offsets xml_i="51477" xml_f="51970" txt_i="35221" txt_f="35714">]. Accordingly, it is prudent to focus on patients with operable disease; these patients have, in general, better performance status (and prognosis) and issues of NSCLC survivorship are becoming increasingly important aspect of multidisciplinary care. A second important consideration was the decision to investigate the efficacy of exercise following completion of, as opposed to, during adjuvant therapy. In our pilot work, aerobic training was associated with a 2% and 11% improvement in VO</offsets><sub><offsets xml_i="51975" xml_f="51981" txt_i="35714" txt_f="35720">2peak </offsets></sub><offsets xml_i="51987" xml_f="52080" txt_i="35720" txt_f="35813">among patients receiving or not receiving chemotherapy, respectively for postoperative NSCLC[</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="52112" xml_f="52114" txt_i="35813" txt_f="35815">17</offsets></xref><offsets xml_i="52121" xml_f="52216" txt_i="35815" txt_f="35910">]. Clearly, without a non-intervention control group, it is not known whether maintenance of VO</offsets><sub><offsets xml_i="52221" xml_f="52227" txt_i="35910" txt_f="35916">2peak </offsets></sub><offsets xml_i="52233" xml_f="52460" txt_i="35916" txt_f="36143">during chemotherapy is important. Nevertheless, given the lack of benefit of exercise training during chemotherapy, subjects in LUNGEVITY will be recruited ≥6 months following the completion of adjuvant therapy, if appropriate.</offsets></p></sec><sec><title><offsets xml_i="52482" xml_f="52499" txt_i="36145" txt_f="36162">Ancillary Studies</offsets></title><p><offsets xml_i="52510" xml_f="53229" txt_i="36163" txt_f="36882">A number of ancillary studies are planned for LUNGEVITY. First, as part of the informed consent process, a sample of white cells (buffy coat) will be collected from each subject in order to conduct genetic studies. A question of great interest that has not yet been addressed in the cancer populations is assessing genetic contributions to inter-individual differences in response to exercise training. Second, we will conduct ancillary study to examine predictors of adherence to the interventions as well as extent of exercise 'drop-in' in the attention control group across different exercise protocols in NSCLC. To address this question, we will adopt the guiding principles of the theory of planned behavior (TPB)[</offsets><xref ref-type="bibr" rid="B50"><offsets xml_i="53261" xml_f="53263" txt_i="36882" txt_f="36884">50</offsets></xref><offsets xml_i="53270" xml_f="53434" txt_i="36884" txt_f="37048">]. This data will be used to inform the design and implementation of future trials. Third, in addition to assessing the physiological mediators of the exercise - VO</offsets><sub><offsets xml_i="53439" xml_f="53445" txt_i="37048" txt_f="37054">2peak </offsets></sub><offsets xml_i="53451" xml_f="54086" txt_i="37054" txt_f="37689">relationship, LUNGEVITY also provides a unique opportunity to examine which psychological variables that may mediate the exercise - PROs relationship. To this end, we will assess whether self-efficacy, affect, and social support mediate the effect of the exercise interventions and attention-control on anticipated improvements in PROs. Finally, we will include pilot studies to investigate the effects of exercise training on changes in peripheral gene expression (from analysis of whole blood mRNA) using high-density mRNA microarrays. Such studies will provide insight into the molecular mechanistic properties of exercise in NSCLC.</offsets></p></sec><sec><title><offsets xml_i="54108" xml_f="54115" txt_i="37691" txt_f="37698">Summary</offsets></title><p><offsets xml_i="54126" xml_f="54271" txt_i="37699" txt_f="37844">The past decade has witnessed a dramatic increase in clinical and research interest of the application of exercise following a cancer diagnosis [</offsets><xref ref-type="bibr" rid="B51"><offsets xml_i="54303" xml_f="54305" txt_i="37844" txt_f="37846">51</offsets></xref><offsets xml_i="54312" xml_f="54313" txt_i="37846" txt_f="37847">-</offsets><xref ref-type="bibr" rid="B58"><offsets xml_i="54345" xml_f="54347" txt_i="37847" txt_f="37849">58</offsets></xref><offsets xml_i="54354" xml_f="54617" txt_i="37849" txt_f="38112">]. Recent systematic reviews conclude that exercise is a safe and feasible supportive intervention to improve symptom control and cardiorespiratory fitness in cancer patients with early-stage disease either during or following the completion of adjuvant therapy [</offsets><xref ref-type="bibr" rid="B59"><offsets xml_i="54649" xml_f="54651" txt_i="38112" txt_f="38114">59</offsets></xref><offsets xml_i="54658" xml_f="54659" txt_i="38114" txt_f="38115">-</offsets><xref ref-type="bibr" rid="B63"><offsets xml_i="54691" xml_f="54693" txt_i="38115" txt_f="38117">63</offsets></xref><offsets xml_i="54700" xml_f="55049" txt_i="38117" txt_f="38466">]. Moreover, recent observational studies provided the first evidence that regular exercise (i.e., 30 minutes of brisk walking at least 5 days/week) may be associated with substantial reductions in cancer-specific mortality and all-cause mortality among patients with early breast and colorectal cancer following the completion of adjuvant therapy [</offsets><xref ref-type="bibr" rid="B64"><offsets xml_i="55081" xml_f="55083" txt_i="38466" txt_f="38468">64</offsets></xref><offsets xml_i="55090" xml_f="55091" txt_i="38468" txt_f="38469">-</offsets><xref ref-type="bibr" rid="B68"><offsets xml_i="55123" xml_f="55125" txt_i="38469" txt_f="38471">68</offsets></xref><offsets xml_i="55132" xml_f="55260" txt_i="38471" txt_f="38599">]. Despite this growing evidence, investigation of the role of exercise training following a diagnosis of NSCLC remains limited.</offsets></p><p><offsets xml_i="55267" xml_f="55501" txt_i="38600" txt_f="38834">The pathophysiology of NSCLC together with conventional therapeutic management is associated with unique and varying degrees of adverse physiological impairments that dramatically reduce patient's ability to tolerate exercise. Poor VO</offsets><sub><offsets xml_i="55506" xml_f="55512" txt_i="38834" txt_f="38840">2peak </offsets></sub><offsets xml_i="55518" xml_f="55967" txt_i="38840" txt_f="39289">likely predisposes to increased susceptibility to other common age-related diseases, greater symptoms, poor QOL, and even premature death. In recent years, a limited number of pilot studies have emerged that provide 'proof-of-principle' that supervised aerobic training is a safe and feasible supportive intervention associated with improvements in cardiopulmonary function and select patient-reported outcomes in postsurgical NSCLC. In addition, VO</offsets><sub><offsets xml_i="55972" xml_f="55978" txt_i="39289" txt_f="39295">2peak </offsets></sub><offsets xml_i="55984" xml_f="56194" txt_i="39295" txt_f="39505">may be a strong, independent predictor of long-term all-cause mortality in this population. Against this background, LUNGEVITY was designed to identify the most effective type of exercise training to improve VO</offsets><sub><offsets xml_i="56199" xml_f="56205" txt_i="39505" txt_f="39511">2peak </offsets></sub><offsets xml_i="56211" xml_f="56920" txt_i="39511" txt_f="40220">and to elucidate the physiologic mechanisms underlying this improvement. To our knowledge, LUNGEVITY will be the first trial to compare different types of exercise training protocols in NSCLC as well as the first to study the effects of exercise on changes in the organ components that govern exercise tolerance in any cancer population. In totality, LUNGEVITY will address many critical unanswered questions regarding the role and mechanistic properties of exercise in NSCLC and will set the stage for more definite trials. In the long-term, we hope that this research will contribute to the establishment of clinical exercise therapy rehabilitation guidelines for patients across the entire NSCLC continuum.</offsets></p></sec></sec><sec><title><offsets xml_i="56948" xml_f="56967" txt_i="40223" txt_f="40242">Competing interests</offsets></title><p><offsets xml_i="56978" xml_f="57036" txt_i="40243" txt_f="40301">The authors declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="57058" xml_f="57080" txt_i="40303" txt_f="40325">Authors' contributions</offsets></title><p><offsets xml_i="57091" xml_f="57643" txt_i="40326" txt_f="40878">LWJ: conception and design, drafting of manuscript, and final approval for publication. NDE: conception and design and final approval for publication. WEK: conception and design and final approval for publication. AP: conception and design and final approval for publication. JC: conception and design and final approval for publication. JAB: conception and design and final approval for publication. BLP: drafting of manuscript and final approval for publication. PSD: conception and design, drafting of manuscript, and final approval for publication.</offsets></p></sec><sec><title><offsets xml_i="57665" xml_f="57688" txt_i="40880" txt_f="40903">Pre-publication history</offsets></title><p><offsets xml_i="57699" xml_f="57763" txt_i="40904" txt_f="40968">The pre-publication history for this paper can be accessed here:</offsets></p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/10/155/prepub"><offsets xml_i="57866" xml_f="57918" txt_i="40969" txt_f="41021">http://www.biomedcentral.com/1471-2407/10/155/prepub</offsets></ext-link></p></sec></body><back><sec><title>Acknowledgements</title><p>This study was supported by the National Institutes of Health (R01 CA138624).</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Woodward</surname><given-names>RM</given-names></name><name><surname>Brown</surname><given-names>ML</given-names></name><name><surname>Stewart</surname><given-names>ST</given-names></name><name><surname>Cronin</surname><given-names>KA</given-names></name><name><surname>Cutler</surname><given-names>DM</given-names></name><article-title>The value of medical interventions for lung cancer in the elderly: results from SEER-CMHSF</article-title><source>Cancer</source><year>2007</year><volume>110</volume><issue>11</issue><fpage>2511</fpage><lpage>2518</lpage><pub-id pub-id-type="doi">10.1002/cncr.23058</pub-id><pub-id pub-id-type="pmid">17955504</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Kenny</surname><given-names>PM</given-names></name><name><surname>King</surname><given-names>MT</given-names></name><name><surname>Viney</surname><given-names>RC</given-names></name><name><surname>Boyer</surname><given-names>MJ</given-names></name><name><surname>Pollicino</surname><given-names>CA</given-names></name><name><surname>McLean</surname><given-names>JM</given-names></name><name><surname>Fulham</surname><given-names>MJ</given-names></name><name><surname>McCaughan</surname><given-names>BC</given-names></name><article-title>Quality of life and survival in the 2 years after surgery for non small-cell lung cancer</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>2</issue><fpage>233</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.07.7230</pub-id><pub-id pub-id-type="pmid">18086802</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Filipczak</surname><given-names>L</given-names></name><name><surname>Chow</surname><given-names>E</given-names></name><article-title>Symptom clusters in cancer patients: a review of the literature</article-title><source>Curr Oncol</source><year>2007</year><volume>14</volume><issue>5</issue><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.3747/co.2007.145</pub-id><pub-id pub-id-type="pmid">17938700</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Paull</surname><given-names>DE</given-names></name><name><surname>Thomas</surname><given-names>ML</given-names></name><name><surname>Meade</surname><given-names>GE</given-names></name><name><surname>Updyke</surname><given-names>GM</given-names></name><name><surname>Arocho</surname><given-names>MA</given-names></name><name><surname>Chin</surname><given-names>HW</given-names></name><name><surname>Adebonojo</surname><given-names>SA</given-names></name><name><surname>Little</surname><given-names>AG</given-names></name><article-title>Determinants of quality of life in patients following pulmonary resection for lung cancer</article-title><source>Am J Surg</source><year>2006</year><volume>192</volume><issue>5</issue><fpage>565</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1016/j.amjsurg.2006.08.019</pub-id><pub-id pub-id-type="pmid">17071185</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Rumble</surname><given-names>ME</given-names></name><name><surname>Keefe</surname><given-names>FJ</given-names></name><name><surname>Edinger</surname><given-names>JD</given-names></name><name><surname>Porter</surname><given-names>LS</given-names></name><name><surname>Garst</surname><given-names>JL</given-names></name><article-title>A pilot study investigating the utility of the cognitive-behavioral model of insomnia in early-stage lung cancer patients</article-title><source>J Pain Symptom Manage</source><year>2005</year><volume>30</volume><issue>2</issue><fpage>160</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1016/j.jpainsymman.2005.02.013</pub-id><pub-id pub-id-type="pmid">16125031</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>WW</given-names></name><name><surname>Lee</surname><given-names>TW</given-names></name><name><surname>Yim</surname><given-names>AP</given-names></name><article-title>Quality of life after lung cancer resection</article-title><source>Thorac Surg Clin</source><year>2004</year><volume>14</volume><issue>3</issue><fpage>353</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1016/S1547-4127(04)00023-4</pub-id><pub-id pub-id-type="pmid">15382767</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Kavanagh</surname><given-names>T</given-names></name><name><surname>Mertens</surname><given-names>DJ</given-names></name><name><surname>Hamm</surname><given-names>LF</given-names></name><name><surname>Beyene</surname><given-names>J</given-names></name><name><surname>Kennedy</surname><given-names>J</given-names></name><name><surname>Corey</surname><given-names>P</given-names></name><name><surname>Shephard</surname><given-names>RJ</given-names></name><article-title>Prediction of long-term prognosis in 12 169 men referred for cardiac rehabilitation</article-title><source>Circulation</source><year>2002</year><volume>106</volume><issue>6</issue><fpage>666</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000024413.15949.ED</pub-id><pub-id pub-id-type="pmid">12163425</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Myers</surname><given-names>J</given-names></name><name><surname>Prakash</surname><given-names>M</given-names></name><name><surname>Froelicher</surname><given-names>V</given-names></name><name><surname>Do</surname><given-names>D</given-names></name><name><surname>Partington</surname><given-names>S</given-names></name><name><surname>Atwood</surname><given-names>JE</given-names></name><article-title>Exercise capacity and mortality among men referred for exercise testing</article-title><source>N Engl J Med</source><year>2002</year><volume>346</volume><issue>11</issue><fpage>793</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa011858</pub-id><pub-id pub-id-type="pmid">11893790</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>LW</given-names></name><name><surname>Eves</surname><given-names>ND</given-names></name><name><surname>Haykowsky</surname><given-names>M</given-names></name><name><surname>Freedland</surname><given-names>SJ</given-names></name><name><surname>Mackey</surname><given-names>JR</given-names></name><article-title>Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction</article-title><source>Lancet Oncol</source><year>2009</year><volume>10</volume><issue>6</issue><fpage>598</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(09)70031-2</pub-id><pub-id pub-id-type="pmid">19482248</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>LW</given-names></name><name><surname>Eves</surname><given-names>ND</given-names></name><name><surname>Waner</surname><given-names>E</given-names></name><name><surname>Joy</surname><given-names>AA</given-names></name><article-title>Exercise therapy across the lung cancer continuum</article-title><source>Curr Oncol Rep</source><year>2009</year><volume>11</volume><issue>4</issue><fpage>255</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1007/s11912-009-0036-0</pub-id><pub-id pub-id-type="pmid">19508829</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Win</surname><given-names>T</given-names></name><name><surname>Jackson</surname><given-names>A</given-names></name><name><surname>Groves</surname><given-names>AM</given-names></name><name><surname>Sharples</surname><given-names>LD</given-names></name><name><surname>Charman</surname><given-names>SC</given-names></name><name><surname>Laroche</surname><given-names>CM</given-names></name><article-title>Comparison of shuttle walk with measured peak oxygen consumption in patients with operable lung cancer</article-title><source>Thorax</source><year>2006</year><volume>61</volume><issue>1</issue><fpage>57</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1136/thx.2005.043547</pub-id><pub-id pub-id-type="pmid">16244091</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Beckles</surname><given-names>MA</given-names></name><name><surname>Spiro</surname><given-names>SG</given-names></name><name><surname>Colice</surname><given-names>GL</given-names></name><name><surname>Rudd</surname><given-names>RM</given-names></name><article-title>The physiologic evaluation of patients with lung cancer being considered for resectional surgery</article-title><source>Chest</source><year>2003</year><volume>123</volume><issue>1 Suppl</issue><fpage>105S</fpage><lpage>114S</lpage><pub-id pub-id-type="doi">10.1378/chest.123.1_suppl.105S</pub-id><pub-id pub-id-type="pmid">12527570</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Beckles</surname><given-names>MA</given-names></name><name><surname>Spiro</surname><given-names>SG</given-names></name><name><surname>Colice</surname><given-names>GL</given-names></name><name><surname>Rudd</surname><given-names>RM</given-names></name><article-title>Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes</article-title><source>Chest</source><year>2003</year><volume>123</volume><issue>1 Suppl</issue><fpage>97S</fpage><lpage>104S</lpage><pub-id pub-id-type="doi">10.1378/chest.123.1_suppl.97S</pub-id><pub-id pub-id-type="pmid">12527569</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Dales</surname><given-names>RE</given-names></name><name><surname>Dionne</surname><given-names>G</given-names></name><name><surname>Leech</surname><given-names>JA</given-names></name><name><surname>Lunau</surname><given-names>M</given-names></name><name><surname>Schweitzer</surname><given-names>I</given-names></name><article-title>Preoperative prediction of pulmonary complications following thoracic surgery</article-title><source>Chest</source><year>1993</year><volume>104</volume><issue>1</issue><fpage>155</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1378/chest.104.1.155</pub-id><pub-id pub-id-type="pmid">8325061</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>LW</given-names></name><name><surname>Eves</surname><given-names>ND</given-names></name><name><surname>Peterson</surname><given-names>BL</given-names></name><name><surname>Garst</surname><given-names>J</given-names></name><name><surname>Crawford</surname><given-names>J</given-names></name><name><surname>West</surname><given-names>MJ</given-names></name><name><surname>Mabe</surname><given-names>S</given-names></name><name><surname>Harpole</surname><given-names>D</given-names></name><name><surname>Kraus</surname><given-names>WE</given-names></name><name><surname>Douglas</surname><given-names>PS</given-names></name><article-title>Safety and feasibility of aerobic training on cardiopulmonary function and quality of life in postsurgical non-small cell lung cancer patients: A pilot study</article-title><source>Cancer</source><year>2008</year><volume>113</volume><issue>12</issue><fpage>3430</fpage><lpage>3439</lpage><pub-id pub-id-type="doi">10.1002/cncr.23967</pub-id><pub-id pub-id-type="pmid">18988290</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Kohman</surname><given-names>L</given-names></name><name><surname>Watson</surname><given-names>D</given-names></name><name><surname>Herndon</surname><given-names>JE</given-names></name><name><surname>Eves</surname><given-names>ND</given-names></name><name><surname>Haithcock</surname><given-names>B</given-names></name><name><surname>Loewen</surname><given-names>G</given-names></name><name><surname>Jones</surname><given-names>LW</given-names></name><article-title>CALGB 140803 - Association between cardiorespiratory fitness and overall survival in operable lung cancer patients: ancillary analysis of protocol 9238</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>15s</issue></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>LW</given-names></name><name><surname>Eves</surname><given-names>ND</given-names></name><name><surname>Peterson</surname><given-names>BL</given-names></name><name><surname>Garst</surname><given-names>J</given-names></name><name><surname>Crawford</surname><given-names>J</given-names></name><name><surname>West</surname><given-names>MJ</given-names></name><name><surname>Mabe</surname><given-names>S</given-names></name><name><surname>Harpole</surname><given-names>D</given-names></name><name><surname>Kraus</surname><given-names>WE</given-names></name><name><surname>Douglas</surname><given-names>PS</given-names></name><article-title>Safety and feasibility of aerobic training on cardiopulmonary function and quality of life in postsurgical nonsmall cell lung cancer patients: a pilot study</article-title><source>Cancer</source><year>2008</year><volume>113</volume><issue>12</issue><fpage>3430</fpage><lpage>3439</lpage><pub-id pub-id-type="doi">10.1002/cncr.23967</pub-id><pub-id pub-id-type="pmid">18988290</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>LW</given-names></name><name><surname>Peddle</surname><given-names>CJ</given-names></name><name><surname>Eves</surname><given-names>ND</given-names></name><name><surname>Haykowsky</surname><given-names>MJ</given-names></name><name><surname>Courneya</surname><given-names>KS</given-names></name><name><surname>Mackey</surname><given-names>JR</given-names></name><name><surname>Joy</surname><given-names>AA</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Winton</surname><given-names>TW</given-names></name><name><surname>Reiman</surname><given-names>T</given-names></name><article-title>Effects of presurgical exercise training on cardiorespiratory fitness among patients undergoing thoracic surgery for malignant lung lesions</article-title><source>Cancer</source><year>2007</year><volume>110</volume><issue>3</issue><fpage>590</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1002/cncr.22830</pub-id><pub-id pub-id-type="pmid">17582629</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Degraff</surname><given-names>AC</given-names><suffix>Jr</suffix></name><name><surname>Taylor</surname><given-names>HF</given-names></name><name><surname>Ord</surname><given-names>JW</given-names></name><name><surname>Chuang</surname><given-names>TH</given-names></name><name><surname>Johnson</surname><given-names>RL</given-names><suffix>Jr</suffix></name><article-title>Exercise Limitation Following Extensive Pulmonary Resection</article-title><source>J Clin Invest</source><year>1965</year><volume>44</volume><fpage>1514</fpage><lpage>1522</lpage><pub-id pub-id-type="doi">10.1172/JCI105258</pub-id><pub-id pub-id-type="pmid">14332164</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Hsia</surname><given-names>CC</given-names></name><name><surname>Carlin</surname><given-names>JI</given-names></name><name><surname>Ramanathan</surname><given-names>M</given-names></name><name><surname>Cassidy</surname><given-names>SS</given-names></name><name><surname>Johnson</surname><given-names>RL</given-names><suffix>Jr</suffix></name><article-title>Estimation of diffusion limitation after pneumonectomy from carbon monoxide diffusing capacity</article-title><source>Respir Physiol</source><year>1991</year><volume>83</volume><issue>1</issue><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/0034-5687(91)90089-2</pub-id><pub-id pub-id-type="pmid">2028103</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Hsia</surname><given-names>CC</given-names></name><name><surname>Herazo</surname><given-names>LF</given-names></name><name><surname>Ramanathan</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>RL</given-names><suffix>Jr</suffix></name><article-title>Cardiopulmonary adaptations to pneumonectomy in dogs. IV. Membrane diffusing capacity and capillary blood volume</article-title><source>J Appl Physiol</source><year>1994</year><volume>77</volume><issue>2</issue><fpage>998</fpage><lpage>1005</lpage><pub-id pub-id-type="pmid">8002557</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Hsia</surname><given-names>CC</given-names></name><name><surname>Dane</surname><given-names>DM</given-names></name><name><surname>Estrera</surname><given-names>AS</given-names></name><name><surname>Wagner</surname><given-names>HE</given-names></name><name><surname>Wagner</surname><given-names>PD</given-names></name><name><surname>Johnson</surname><given-names>RL</given-names><suffix>Jr</suffix></name><article-title>Shifting sources of functional limitation following extensive (70%) lung resection</article-title><source>J Appl Physiol</source><year>2008</year><volume>104</volume><issue>4</issue><fpage>1069</fpage><lpage>1079</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.01198.2007</pub-id><pub-id pub-id-type="pmid">18258800</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Wagner</surname><given-names>PD</given-names></name><article-title>Skeletal muscles in chronic obstructive pulmonary disease: deconditioning, or myopathy?</article-title><source>Respirology</source><year>2006</year><volume>11</volume><issue>6</issue><fpage>681</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1843.2006.00939.x</pub-id><pub-id pub-id-type="pmid">17052294</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><article-title>American College of Sports Medicine Position Stand. The recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness, and flexibility in healthy adults</article-title><source>Med Sci Sports Exerc</source><year>1998</year><volume>30</volume><issue>6</issue><fpage>975</fpage><lpage>991</lpage><pub-id pub-id-type="doi">10.1097/00005768-199806000-00032</pub-id><pub-id pub-id-type="pmid">9624661</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Pollock</surname><given-names>ML</given-names></name><name><surname>Franklin</surname><given-names>BA</given-names></name><name><surname>Balady</surname><given-names>GJ</given-names></name><name><surname>Chaitman</surname><given-names>BL</given-names></name><name><surname>Fleg</surname><given-names>JL</given-names></name><name><surname>Fletcher</surname><given-names>B</given-names></name><name><surname>Limacher</surname><given-names>M</given-names></name><name><surname>Pina</surname><given-names>IL</given-names></name><name><surname>Stein</surname><given-names>RA</given-names></name><name><surname>Williams</surname><given-names>M</given-names></name><article-title>AHA Science Advisory. Resistance exercise in individuals with and without cardiovascular disease: benefits, rationale, safety, and prescription: An advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association; Position paper endorsed by the American College of Sports Medicine</article-title><source>Circulation</source><year>2000</year><volume>101</volume><issue>7</issue><fpage>828</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">10683360</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Fodor</surname><given-names>JG</given-names></name><name><surname>Whitmore</surname><given-names>B</given-names></name><name><surname>Leenen</surname><given-names>F</given-names></name><name><surname>Larochelle</surname><given-names>P</given-names></name><article-title>Lifestyle modifications to prevent and control hypertension. 5. Recommendations on dietary salt. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada</article-title><source>Cmaj</source><year>1999</year><volume>160</volume><issue>9 Suppl</issue><fpage>S29</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">10333851</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Deschenes</surname><given-names>MR</given-names></name><name><surname>Kraemer</surname><given-names>WJ</given-names></name><article-title>Performance and physiologic adaptations to resistance training</article-title><source>Am J Phys Med Rehabil</source><year>2002</year><volume>81</volume><issue>11 Suppl</issue><fpage>S3</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1097/00002060-200211001-00003</pub-id><pub-id pub-id-type="pmid">12409807</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>King</surname><given-names>L</given-names></name><article-title>The effects of resistance exercise on skeletal muscle abnormalities in patients with advanced heart failure</article-title><source>Prog Cardiovasc Nurs</source><year>2001</year><volume>16</volume><issue>4</issue><fpage>142</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1111/j.0889-7204.2001.00616.x</pub-id><pub-id pub-id-type="pmid">11684905</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Hepple</surname><given-names>RT</given-names></name><name><surname>Mackinnon</surname><given-names>SL</given-names></name><name><surname>Goodman</surname><given-names>JM</given-names></name><name><surname>Thomas</surname><given-names>SG</given-names></name><name><surname>Plyley</surname><given-names>MJ</given-names></name><article-title>Resistance and aerobic training in older men: effects on VO2peak and the capillary supply to skeletal muscle</article-title><source>J Appl Physiol</source><year>1997</year><volume>82</volume><issue>4</issue><fpage>1305</fpage><lpage>1310</lpage><pub-id pub-id-type="pmid">9104869</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Hepple</surname><given-names>RT</given-names></name><name><surname>Mackinnon</surname><given-names>SL</given-names></name><name><surname>Thomas</surname><given-names>SG</given-names></name><name><surname>Goodman</surname><given-names>JM</given-names></name><name><surname>Plyley</surname><given-names>MJ</given-names></name><article-title>Quantitating the capillary supply and the response to resistance training in older men</article-title><source>Pflugers Arch</source><year>1997</year><volume>433</volume><issue>3</issue><fpage>238</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1007/s004240050273</pub-id><pub-id pub-id-type="pmid">9064638</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Hagerman</surname><given-names>FC</given-names></name><name><surname>Walsh</surname><given-names>SJ</given-names></name><name><surname>Staron</surname><given-names>RS</given-names></name><name><surname>Hikida</surname><given-names>RS</given-names></name><name><surname>Gilders</surname><given-names>RM</given-names></name><name><surname>Murray</surname><given-names>TF</given-names></name><name><surname>Toma</surname><given-names>K</given-names></name><name><surname>Ragg</surname><given-names>KE</given-names></name><article-title>Effects of high-intensity resistance training on untrained older men. I. Strength, cardiovascular, and metabolic responses</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2000</year><volume>55</volume><issue>7</issue><fpage>B336</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">10898247</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Campos</surname><given-names>GE</given-names></name><name><surname>Luecke</surname><given-names>TJ</given-names></name><name><surname>Wendeln</surname><given-names>HK</given-names></name><name><surname>Toma</surname><given-names>K</given-names></name><name><surname>Hagerman</surname><given-names>FC</given-names></name><name><surname>Murray</surname><given-names>TF</given-names></name><name><surname>Ragg</surname><given-names>KE</given-names></name><name><surname>Ratamess</surname><given-names>NA</given-names></name><name><surname>Kraemer</surname><given-names>WJ</given-names></name><name><surname>Staron</surname><given-names>RS</given-names></name><article-title>Muscular adaptations in response to three different resistance-training regimens: specificity of repetition maximum training zones</article-title><source>Eur J Appl Physiol</source><year>2002</year><volume>88</volume><issue>1-2</issue><fpage>50</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1007/s00421-002-0681-6</pub-id><pub-id pub-id-type="pmid">12436270</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Haykowsky</surname><given-names>M</given-names></name><name><surname>Muhll</surname><given-names>I Vonder</given-names></name><name><surname>Ezekowitz</surname><given-names>J</given-names></name><name><surname>Armstrong</surname><given-names>P</given-names></name><article-title>Supervised exercise training improves aerobic capacity and muscle strength in older women with heart failure</article-title><source>Can J Cardiol</source><year>2005</year><volume>21</volume><issue>14</issue><fpage>1277</fpage><lpage>1280</lpage><pub-id pub-id-type="pmid">16341296</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Lawrenson</surname><given-names>L</given-names></name><name><surname>Hoff</surname><given-names>J</given-names></name><name><surname>Richardson</surname><given-names>RS</given-names></name><article-title>Aging attenuates vascular and metabolic plasticity but does not limit improvement in muscle VO(2) max</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2004</year><volume>286</volume><issue>4</issue><fpage>H1565</fpage><lpage>1572</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.01070.2003</pub-id><pub-id pub-id-type="pmid">14684375</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Boutron</surname><given-names>I</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Ravaud</surname><given-names>P</given-names></name><article-title>Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration</article-title><source>Ann Intern Med</source><year>2008</year><volume>148</volume><issue>4</issue><fpage>295</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">18283207</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>LW</given-names></name><name><surname>Eves</surname><given-names>ND</given-names></name><name><surname>Hayowsky</surname><given-names>M</given-names></name><name><surname>Joy</surname><given-names>AA</given-names></name><name><surname>Douglas</surname><given-names>PS</given-names></name><article-title>Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations</article-title><source>Lancet Oncol</source><year>2008</year><volume>9</volume><issue>8</issue><fpage>757</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(08)70195-5</pub-id><pub-id pub-id-type="pmid">18672211</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>LW</given-names></name><name><surname>Eves</surname><given-names>ND</given-names></name><name><surname>Mackey</surname><given-names>JR</given-names></name><name><surname>Peddle</surname><given-names>CJ</given-names></name><name><surname>Haykowsky</surname><given-names>M</given-names></name><name><surname>Joy</surname><given-names>AA</given-names></name><name><surname>Courneya</surname><given-names>KS</given-names></name><name><surname>Tankel</surname><given-names>K</given-names></name><name><surname>Spratlin</surname><given-names>J</given-names></name><name><surname>Reiman</surname><given-names>T</given-names></name><article-title>Safety and feasibility of cardiopulmonary exercise testing in patients with advanced cancer</article-title><source>Lung Cancer</source><year>2007</year><volume>55</volume><issue>2</issue><fpage>225</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2006.10.006</pub-id><pub-id pub-id-type="pmid">17113185</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="other"><name><surname>Jones</surname><given-names>LW</given-names></name><name><surname>Garst</surname><given-names>J</given-names></name><name><surname>Eves</surname><given-names>ND</given-names></name><name><surname>West</surname><given-names>M</given-names></name><name><surname>Mabe</surname><given-names>S</given-names></name><name><surname>Crawford</surname><given-names>J</given-names></name><article-title>Effect of aerobic exericse training on cardiorespiratory fitness and quality of life in postsurgical non-small cell lung cancer patients</article-title><source>Journal of Clinical Oncology: 2008 ASCO Annual Meeting Proceedings (abstract #7577)</source><year>2008</year></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Cella</surname><given-names>DF</given-names></name><name><surname>Bonomi</surname><given-names>AE</given-names></name><name><surname>Lloyd</surname><given-names>SR</given-names></name><name><surname>Tulsky</surname><given-names>DS</given-names></name><name><surname>Kaplan</surname><given-names>E</given-names></name><name><surname>Bonomi</surname><given-names>P</given-names></name><article-title>Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument</article-title><source>Lung Cancer</source><year>1995</year><volume>12</volume><issue>3</issue><fpage>199</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/0169-5002(95)00450-F</pub-id><pub-id pub-id-type="pmid">7655830</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Cella</surname><given-names>D</given-names></name><article-title>The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue</article-title><source>Semin Hematol</source><year>1997</year><volume>34</volume><issue>3 Suppl 2</issue><fpage>13</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">9253779</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Akechi</surname><given-names>T</given-names></name><name><surname>Okuyama</surname><given-names>T</given-names></name><name><surname>Nishiwaki</surname><given-names>Y</given-names></name><name><surname>Uchitomi</surname><given-names>Y</given-names></name><article-title>Development and validation of the Cancer Dyspnoea Scale: a multidimensional, brief, self-rating scale</article-title><source>Br J Cancer</source><year>2000</year><volume>82</volume><issue>4</issue><fpage>800</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1054/bjoc.1999.1002</pub-id><pub-id pub-id-type="pmid">10732749</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Cesario</surname><given-names>A</given-names></name><name><surname>Ferri</surname><given-names>L</given-names></name><name><surname>Galetta</surname><given-names>D</given-names></name><name><surname>Pasqua</surname><given-names>F</given-names></name><name><surname>Bonassi</surname><given-names>S</given-names></name><name><surname>Clini</surname><given-names>E</given-names></name><name><surname>Biscione</surname><given-names>G</given-names></name><name><surname>Cardaci</surname><given-names>V</given-names></name><name><surname>di Toro</surname><given-names>S</given-names></name><name><surname>Zarzana</surname><given-names>A</given-names></name><article-title>Post-operative respiratory rehabilitation after lung resection for non-small cell lung cancer</article-title><source>Lung Cancer</source><year>2007</year><volume>57</volume><issue>1</issue><fpage>118</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2007.03.022</pub-id><pub-id pub-id-type="pmid">17475363</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Bredin</surname><given-names>M</given-names></name><name><surname>Corner</surname><given-names>J</given-names></name><name><surname>Krishnasamy</surname><given-names>M</given-names></name><name><surname>Plant</surname><given-names>H</given-names></name><name><surname>Bailey</surname><given-names>C</given-names></name><name><surname>A'Hern</surname><given-names>R</given-names></name><article-title>Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer</article-title><source>Bmj</source><year>1999</year><volume>318</volume><issue>7188</issue><fpage>901</fpage><lpage>904</lpage><pub-id pub-id-type="pmid">10102851</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Farmer</surname><given-names>ME</given-names></name><name><surname>Locke</surname><given-names>BZ</given-names></name><name><surname>Moscicki</surname><given-names>EK</given-names></name><name><surname>Dannenberg</surname><given-names>AL</given-names></name><name><surname>Larson</surname><given-names>DB</given-names></name><name><surname>Radloff</surname><given-names>LS</given-names></name><article-title>Physical activity and depressive symptoms: the NHANES I Epidemiologic Follow-up Study</article-title><source>Am J Epidemiol</source><year>1988</year><volume>128</volume><issue>6</issue><fpage>1340</fpage><lpage>1351</lpage><pub-id pub-id-type="pmid">3264110</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Kreider</surname><given-names>ME</given-names></name><name><surname>Grippi</surname><given-names>MA</given-names></name><article-title>Impact of the new ATS/ERS pulmonary function test interpretation guidelines</article-title><source>Respir Med</source><year>2007</year><volume>101</volume><issue>11</issue><fpage>2336</fpage><lpage>2342</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2007.06.019</pub-id><pub-id pub-id-type="pmid">17686622</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Parisi</surname><given-names>AF</given-names></name><name><surname>Moynihan</surname><given-names>PF</given-names></name><name><surname>Feldman</surname><given-names>CL</given-names></name><name><surname>Folland</surname><given-names>ED</given-names></name><article-title>Approaches to determination of left ventricular volume and ejection fraction by real-time two-dimensional echocardiography</article-title><source>Clin Cardiol</source><year>1979</year><volume>2</volume><issue>4</issue><fpage>257</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1002/clc.4960020404</pub-id><pub-id pub-id-type="pmid">262574</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Schiller</surname><given-names>NB</given-names></name><name><surname>Acquatella</surname><given-names>H</given-names></name><name><surname>Ports</surname><given-names>TA</given-names></name><name><surname>Drew</surname><given-names>D</given-names></name><name><surname>Goerke</surname><given-names>J</given-names></name><name><surname>Ringertz</surname><given-names>H</given-names></name><name><surname>Silverman</surname><given-names>NH</given-names></name><name><surname>Brundage</surname><given-names>B</given-names></name><name><surname>Botvinick</surname><given-names>EH</given-names></name><name><surname>Boswell</surname><given-names>R</given-names></name><article-title>Left ventricular volume from paired biplane two-dimensional echocardiography</article-title><source>Circulation</source><year>1979</year><volume>60</volume><issue>3</issue><fpage>547</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">455617</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>Duscha</surname><given-names>BD</given-names></name><name><surname>Annex</surname><given-names>BH</given-names></name><name><surname>Green</surname><given-names>HJ</given-names></name><name><surname>Pippen</surname><given-names>AM</given-names></name><name><surname>Kraus</surname><given-names>WE</given-names></name><article-title>Deconditioning fails to explain peripheral skeletal muscle alterations in men with chronic heart failure</article-title><source>J Am Coll Cardiol</source><year>2002</year><volume>39</volume><issue>7</issue><fpage>1170</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(02)01740-0</pub-id><pub-id pub-id-type="pmid">11923042</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>Holm</surname><given-names>S</given-names></name><article-title>A simple sequentially rejective multiple test procedure</article-title><source>Scandinavian Journal of Statistics</source><year>1979</year><volume>6</volume><fpage>65</fpage><lpage>70</lpage></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><name><surname>Ajzen</surname><given-names>I</given-names></name><article-title>Nature and operation of attitudes</article-title><source>Annu Rev Psychol</source><year>2001</year><volume>52</volume><fpage>27</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1146/annurev.psych.52.1.27</pub-id><pub-id pub-id-type="pmid">11148298</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><name><surname>Irwin</surname><given-names>ML</given-names></name><name><surname>Varma</surname><given-names>K</given-names></name><name><surname>Alvarez-Reeves</surname><given-names>M</given-names></name><name><surname>Cadmus</surname><given-names>L</given-names></name><name><surname>Wiley</surname><given-names>A</given-names></name><name><surname>Chung</surname><given-names>GG</given-names></name><name><surname>Dipietro</surname><given-names>L</given-names></name><name><surname>Mayne</surname><given-names>ST</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><article-title>Randomized Controlled Trial of Aerobic Exercise on Insulin and Insulin-like Growth Factors in Breast Cancer Survivors: The Yale Exercise and Survivorship Study</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2009</year><volume>18</volume><issue>1</issue><fpage>306</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-08-0531</pub-id><pub-id pub-id-type="pmid">19124513</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><name><surname>Bicego</surname><given-names>D</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name><name><surname>Ruddick</surname><given-names>M</given-names></name><name><surname>Storey</surname><given-names>D</given-names></name><name><surname>Wong</surname><given-names>C</given-names></name><name><surname>Harris</surname><given-names>SR</given-names></name><article-title>Effects of exercise on quality of life in women living with breast cancer: a systematic review</article-title><source>Breast J</source><year>2009</year><volume>15</volume><issue>1</issue><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1111/j.1524-4741.2008.00670.x</pub-id><pub-id pub-id-type="pmid">19120381</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><name><surname>Reigle</surname><given-names>BS</given-names></name><name><surname>Wonders</surname><given-names>K</given-names></name><article-title>Breast cancer and the role of exercise in women</article-title><source>Methods Mol Biol</source><year>2009</year><volume>472</volume><fpage>169</fpage><lpage>189</lpage><comment>full_text</comment><pub-id pub-id-type="pmid">19107433</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><name><surname>Ligibel</surname><given-names>JA</given-names></name><name><surname>Partridge</surname><given-names>A</given-names></name><name><surname>Giobbie-Hurder</surname><given-names>A</given-names></name><name><surname>Golshan</surname><given-names>M</given-names></name><name><surname>Emmons</surname><given-names>K</given-names></name><name><surname>Winer</surname><given-names>EP</given-names></name><article-title>Physical Activity Behaviors in Women with Newly Diagnosed Ductal Carcinoma-In-Situ</article-title><source>Ann Surg Oncol</source><year>2008</year><volume>20</volume><issue>8</issue><fpage>1523</fpage><lpage>8</lpage></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><name><surname>Alfano</surname><given-names>CM</given-names></name><name><surname>Smith</surname><given-names>AW</given-names></name><name><surname>Irwin</surname><given-names>ML</given-names></name><name><surname>Bowen</surname><given-names>DJ</given-names></name><name><surname>Sorensen</surname><given-names>B</given-names></name><name><surname>Reeve</surname><given-names>BB</given-names></name><name><surname>Meeske</surname><given-names>KA</given-names></name><name><surname>Bernstein</surname><given-names>L</given-names></name><name><surname>Baumgartner</surname><given-names>KB</given-names></name><name><surname>Ballard-Barbash</surname><given-names>R</given-names></name><article-title>Physical activity, long-term symptoms, and physical health-related quality of life among breast cancer survivors: a prospective analysis</article-title><source>J Cancer Surviv</source><year>2007</year><volume>1</volume><issue>2</issue><fpage>116</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1007/s11764-007-0014-1</pub-id><pub-id pub-id-type="pmid">18648952</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><name><surname>Alfano</surname><given-names>CM</given-names></name><name><surname>Day</surname><given-names>JM</given-names></name><name><surname>Katz</surname><given-names>ML</given-names></name><name><surname>Herndon</surname><given-names>JE</given-names></name><name><surname>Bittoni</surname><given-names>MA</given-names></name><name><surname>Oliveri</surname><given-names>JM</given-names></name><name><surname>Donohue</surname><given-names>K</given-names></name><name><surname>Paskett</surname><given-names>ED</given-names></name><article-title>Exercise and dietary change after diagnosis and cancer-related symptoms in long-term survivors of breast cancer: CALGB 79804</article-title><source>Psychooncology</source><year>2009</year><volume>18</volume><issue>2</issue><fpage>128</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1002/pon.1378</pub-id><pub-id pub-id-type="pmid">18536022</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><name><surname>Demark-Wahnefried</surname><given-names>W</given-names></name><name><surname>Case</surname><given-names>LD</given-names></name><name><surname>Blackwell</surname><given-names>K</given-names></name><name><surname>Marcom</surname><given-names>PK</given-names></name><name><surname>Kraus</surname><given-names>W</given-names></name><name><surname>Aziz</surname><given-names>N</given-names></name><name><surname>Snyder</surname><given-names>DC</given-names></name><name><surname>Giguere</surname><given-names>JK</given-names></name><name><surname>Shaw</surname><given-names>E</given-names></name><article-title>Results of a diet/exercise feasibility trial to prevent adverse body composition change in breast cancer patients on adjuvant chemotherapy</article-title><source>Clin Breast Cancer</source><year>2008</year><volume>8</volume><issue>1</issue><fpage>70</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.3816/CBC.2008.n.005</pub-id><pub-id pub-id-type="pmid">18501061</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><name><surname>Ligibel</surname><given-names>JA</given-names></name><name><surname>Campbell</surname><given-names>N</given-names></name><name><surname>Partridge</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>WY</given-names></name><name><surname>Salinardi</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Adloff</surname><given-names>K</given-names></name><name><surname>Keshaviah</surname><given-names>A</given-names></name><name><surname>Winer</surname><given-names>EP</given-names></name><article-title>Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>6</issue><fpage>907</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.12.7357</pub-id><pub-id pub-id-type="pmid">18281663</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><name><surname>Ballard-Barbash</surname><given-names>R</given-names></name><name><surname>McTiernan</surname><given-names>A</given-names></name><article-title>Is the whole larger than the sum of the parts? The promise of combining physical activity and diet to improve cancer outcomes</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><issue>17</issue><fpage>2335</fpage><lpage>2337</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.10.7326</pub-id><pub-id pub-id-type="pmid">17557943</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><name><surname>Ingram</surname><given-names>C</given-names></name><name><surname>Courneya</surname><given-names>KS</given-names></name><name><surname>Kingston</surname><given-names>D</given-names></name><article-title>The effects of exercise on body weight and composition in breast cancer survivors: an integrative systematic review</article-title><source>Oncol Nurs Forum</source><year>2006</year><volume>33</volume><issue>5</issue><fpage>937</fpage><lpage>947</lpage><comment>quiz 948-950</comment><pub-id pub-id-type="doi">10.1188/06.ONF.937-950</pub-id><pub-id pub-id-type="pmid">16955122</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><name><surname>McNeely</surname><given-names>ML</given-names></name><name><surname>Campbell</surname><given-names>KL</given-names></name><name><surname>Rowe</surname><given-names>BH</given-names></name><name><surname>Klassen</surname><given-names>TP</given-names></name><name><surname>Mackey</surname><given-names>JR</given-names></name><name><surname>Courneya</surname><given-names>KS</given-names></name><article-title>Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis</article-title><source>Cmaj</source><year>2006</year><volume>175</volume><issue>1</issue><fpage>34</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">16818906</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><name><surname>Galvao</surname><given-names>DA</given-names></name><name><surname>Newton</surname><given-names>RU</given-names></name><article-title>Review of exercise intervention studies in cancer patients</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><issue>4</issue><fpage>899</fpage><lpage>909</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.06.085</pub-id><pub-id pub-id-type="pmid">15681536</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><name><surname>Jones</surname><given-names>LW</given-names></name><name><surname>Demark-Wahnefried</surname><given-names>W</given-names></name><article-title>Diet, exercise, and complementary therapies after primary treatment for cancer</article-title><source>Lancet Oncol</source><year>2006</year><volume>7</volume><issue>12</issue><fpage>1017</fpage><lpage>1026</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(06)70976-7</pub-id><pub-id pub-id-type="pmid">17138223</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><name><surname>Sternfeld</surname><given-names>B</given-names></name><name><surname>Weltzien</surname><given-names>E</given-names></name><name><surname>Quesenberry</surname><given-names>CP</given-names><suffix>Jr</suffix></name><name><surname>Castillo</surname><given-names>AL</given-names></name><name><surname>Kwan</surname><given-names>M</given-names></name><name><surname>Slattery</surname><given-names>ML</given-names></name><name><surname>Caan</surname><given-names>BJ</given-names></name><article-title>Physical Activity and Risk of Recurrence and Mortality in Breast Cancer Survivors: Findings from the LACE Study</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2009</year><volume>18</volume><issue>1</issue><fpage>87</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-08-0595</pub-id><pub-id pub-id-type="pmid">19124485</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><name><surname>Irwin</surname><given-names>ML</given-names></name><name><surname>Smith</surname><given-names>AW</given-names></name><name><surname>McTiernan</surname><given-names>A</given-names></name><name><surname>Ballard-Barbash</surname><given-names>R</given-names></name><name><surname>Cronin</surname><given-names>K</given-names></name><name><surname>Gilliland</surname><given-names>FD</given-names></name><name><surname>Baumgartner</surname><given-names>RN</given-names></name><name><surname>Baumgartner</surname><given-names>KB</given-names></name><name><surname>Bernstein</surname><given-names>L</given-names></name><article-title>Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: the health, eating, activity, and lifestyle study</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>24</issue><fpage>3958</fpage><lpage>3964</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.15.9822</pub-id><pub-id pub-id-type="pmid">18711185</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><name><surname>Holick</surname><given-names>CN</given-names></name><name><surname>Newcomb</surname><given-names>PA</given-names></name><name><surname>Trentham-Dietz</surname><given-names>A</given-names></name><name><surname>Titus-Ernstoff</surname><given-names>L</given-names></name><name><surname>Bersch</surname><given-names>AJ</given-names></name><name><surname>Stampfer</surname><given-names>MJ</given-names></name><name><surname>Baron</surname><given-names>JA</given-names></name><name><surname>Egan</surname><given-names>KM</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><article-title>Physical activity and survival after diagnosis of invasive breast cancer</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2008</year><volume>17</volume><issue>2</issue><fpage>379</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-07-0771</pub-id><pub-id pub-id-type="pmid">18250341</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><name><surname>Pierce</surname><given-names>JP</given-names></name><name><surname>Stefanick</surname><given-names>ML</given-names></name><name><surname>Flatt</surname><given-names>SW</given-names></name><name><surname>Natarajan</surname><given-names>L</given-names></name><name><surname>Sternfeld</surname><given-names>B</given-names></name><name><surname>Madlensky</surname><given-names>L</given-names></name><name><surname>Al-Delaimy</surname><given-names>WK</given-names></name><name><surname>Thomson</surname><given-names>CA</given-names></name><name><surname>Kealey</surname><given-names>S</given-names></name><name><surname>Hajek</surname><given-names>R</given-names></name><article-title>Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><issue>17</issue><fpage>2345</fpage><lpage>2351</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.08.6819</pub-id><pub-id pub-id-type="pmid">17557947</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><name><surname>Holmes</surname><given-names>MD</given-names></name><name><surname>Chen</surname><given-names>WY</given-names></name><name><surname>Feskanich</surname><given-names>D</given-names></name><name><surname>Kroenke</surname><given-names>CH</given-names></name><name><surname>Colditz</surname><given-names>GA</given-names></name><article-title>Physical activity and survival after breast cancer diagnosis</article-title><source>Jama</source><year>2005</year><volume>293</volume><issue>20</issue><fpage>2479</fpage><lpage>2486</lpage><pub-id pub-id-type="doi">10.1001/jama.293.20.2479</pub-id><pub-id pub-id-type="pmid">15914748</pub-id></mixed-citation></ref></ref-list></back></article>